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Apoptosis is a well-orchestrated programmed cell death. In cancer biology 
the evasion of apoptosis has been considered as one of the key events for 
tumour development and paradoxically, studies also show that apoptosis has 
detrimental effects that may even promote cancer. High rates of apoptosis 
have been observed in many cancers and aggressive B cell lymphoma 
(prototypically Burkitt’s lymphoma (BL)) present characteristic ‘starry sky’ 
appearance due to extensive apoptotic tumour cells engulfed by infiltrating 
tumour-associated macrophages (TAM). Previous work using a murine BL 
cell model has shown that constitutive apoptosis promotes both angiogenesis 
and the accumulation of pro-tumour TAMs. However, the detailed cellular 
and molecular mechanisms underlying how apoptosis fosters this pro-tumour 
growth microenvironment are still not fully understood, especially the role of 
apoptosis during early steps of tumour initiation. The aim of this project is to 
establish an in vivo model system to dissect the mechanisms as to how 
apoptotic B lymphoma cells enhance angiogenesis and how apoptotic B 
lymphoma cells interact with cells within the host microenvironment to 
promote tumour progression.  
 
Zebrafish (Danio Rerio), a small tropical fresh water fish, has become 
increasingly popular as a biomedical research model organism. Not only is it 
amenable for genetic manipulation, but also due to its transparency in the 
larval stages, is one of the most important models for in vivo live imaging 
studies. Therefore efforts were made to establish a novel transgenic B 
lymphoma model in zebrafish. Complementary to the transgenic model, I 
also established a Xenograft model using a B lymphoma cell line BL2 and its 
apoptosis resistant derivative BL2-bcl2 cell lines.  
 
Using a Tol2 based transgenesis system and zebrafish promoter for IgM 
heavy chain, I have generated transgenic zebrafish with either constitutive B 
cells expressing oncogenic cmyc, Tg (IgM1::cmyc-eGFP), or a tamoxifen 
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inducible version, Tg(IgM1::CreERT2/IgM::lox-H2BmCherry-lox-cmyc-eGFP) 
which allows induction of oncogenic cmyc expression in B-cells with precise  
temporal control. Unfortunately, neither of these models developed B cell 
lymphoma, and fish appear to be generally healthy. Although flow cytometic 
analysis showed normal expression of the transgene in Tg(IgM::lox-
H2BmCherry-lox-cmyc-eGFP), further analysis of the constitutive model 
failed to detect any CMYC expressing eGFP positive B-cells in the head-
kidney. Therefore, unexpectedly IgM driven cmyc expression in zebrafish 
might drive B-cell death instead of B-cell malignancy. This is in contrast to 
the mouse B lymphoma model. 
 
More work is needed in choosing a suitable promoter and/or oncogene 
combination to generate a transgenic zebrafish B lymphoma model. 
 
Xenograft models using zebrafish larvae provided an additional opportunity 
to study interaction between tumour cell and cells within the tumour 
microenvironment. Available transgenic reporter zebrafish strains labelling 
various cell lineages facilitate in vivo imaging of host cellular responses to B 
lymphoma cells. In order to identify putative roles that apoptotic tumour cells 
might play in the tumour microenvironment, I have established a reliable and 
consistent xenograft protocol to graft tumour cells into yolk sack of 2 days 
post fertilization (dpf) zebrafish larvae. Consistent with previous observations 
in mice, BL2 (an apoptotic prone lymphoma cell line) cells survive better than 
their apoptotic resistant derivative BL2-bcl2 (over-expressing bcl2 in BL2 
cells). However, the overall longest survival time is no more than 4 days post 
grafting even with BL2 cells. A possible explanation for this could be lack of 
some key B cell survival factors in zebrafish larvae, as normally mature B 
cells do not develop until two weeks post fertilization.  The mouse models of 
BL indicate that TAMs have been attracted by apoptotic BL cells and 
accumulate at the BL microenvironment. To evaluate whether macrophages 
modulated by apoptotic cells promote BL survival in the zebrafish model, 
human monocyte-derived macrophages were activated by either apoptotic 
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BL2 cells or IFN-γ / lipopolysaccharide (LPS) and co-injected with BL2 cells 
into zebrafish. Results showed that macrophages activated by apoptotic BL2 
cells, but not IFN-γ /LPS, enhanced the survival of BL2 cells. 
 
In the next part I further investigated how apoptotic BL2 cells might modulate 
macrophages and the tumour microenvironment. Extracellular vesicles (EVs) 
are small membrane-bounded vesicles whose molecular profile is regulated 
by their cellular origin and the types of stimuli. EVs have been shown to be 
critical messengers in tumor progression and metastasis. The study of 
apoptosis-induced EVs (Apo-EVs) is sparse. I hypothesised that EVs 
released by apoptotic cells might mediate their pro-tumourigenesis 
properties. I used a recently developed novel protocol in my laboratory to 
isolate Apo-EVs from BL2 cells. EVs from apoptosis resistant BL2-bcl2 cells 
(non-Apo-EVs) were used as a control. I show here for the first time that Apo-
EVs are pro-angiogenic in vivo. Further analysis of the secretome from 
apoptotic BL2 cells as well as their Apo-EVs indicates that soluble protein 
component(s) mediate the pro-angiogenic function. Combining macrophage 
reporter fish Tg(mpeg1::mCherry) with TNFα reporter Tg(tnfα::eGFP), I show 
that Apo-EVs promote macrophage activation but not TNFα in vivo.  
 
In conclusion, this project suggests that apoptotic tumour cells execute their 
pro-oncogenic functions by modulating macrophage activation, enhancing 
tumour angiogenesis, possibly through releasing Apo-EVs.  Apo-EVs are 
recognized as a key player in fostering a pro-tumour growth 
microenvironment. Thus a further understanding of how apoptotic cells exert 
their tumour promoting roles will help us to optimise cancer therapy by 
maximizing tumour cell death while minimizing unwanted pro-tumorigenic 
effects. The models established during this project may be used to identify 





Apoptosis is a form of cell suicide that was first described by Pathology 
Professor A.R.Currie in Aberdeen for tumour cells, but is now recognised to 
occur in normal cell development as well.  In cancer where cell proliferation 
exceeds cell death causing the accumulation of transformed cells, it is 
considered to have a positive role for health. However, in several cancers, 
studies showed that apoptosis can promote tumour growth. For example, in 
Burkitt’s lymphoma (BL), a type of aggressive B cell lymphoma, extensive 
apoptotic tumours are engulfed by macrophages (leukocytes that eat dead 
cells) and these apoptotic cells enhance tumour vessel growth. How these 
apoptotic tumour cells interact with macrophages and enhance tumour blood 
vessel growth are the main questions that this project is addressed to. 
 
This project aimed to establish an in vivo animal system offering the 
opportunity to directly observe tumour growth events. A small tropical fresh 
water fish, zebrafish (Danio Rerio) was chosen due to its transparency in the 
larval stage and amenability for genetic manipulation.  
 
I have generated genetically modified (GM) zebrafish whose B cells express 
a cancer gene called cmyc constitutively or temporally. Unfortunately, neither 
of these models developed B cell lymphoma, and fish appear to be generally 
healthy. These models indicated that other factors are needed to initiate B 
cell lymphoma as in the human. 
 
I have also generated xenograft (foreign tissue grafts) by transplantation of 
human tumour cells into zebrafish.  BL2 cells (an apoptotic prone lymphoma 
cell line) can survive better than their apoptosis-inhibited counterparts in 
zebrafish. However, BL2 cells cannot live longer than 4 days in zebrafish. To 
see what are the potential elements in the tumour that help tumour cell 
survive, macrophages, were co-injected with BL2 into zebrafish. Interestingly, 
macrophages that were co-cultured with apoptotic BL2 cells could help BL2 
cells survive. As macrophages are highly plastic cells with a spectrum of 
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functional activities, apoptotic tumour cells seem to modulate them into a pro-
tumour type. To see what are the other ways that apoptotic tumour cells 
modulate the tumour microenvironment, small membrane-bounded vesicles 
(EVs) released from apoptotic tumour cells were separated and injected into 
zebrafish and they showed an ability to promote tumour vessel growth. 
Furthermore, these apoptosis-induced EVs also showed an ability to 
modulate macrophages. 
 
In conclusion, this project suggests that apoptotic tumour cells can modulate 
the tumour microenvironment to promote tumour growth by enhancing 
tumour vessel growth, changing macrophage function and they may achieve 
these by releasing EVs. A further understanding of apoptosis in cancer may 
help us to optimise anti-cancer therapy by maximizing tumour cell death 
while minimizing unwanted pro-tumorigenic effects 
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Chapter 1 Introduction 
1.1 B cell lymphoma 
1.1.1 General characteristics 
About 20 new cases of lymphoma are diagnosed per 100,000 people every 
year in the western world and approximately 95% of them are of B- cell origin 
(Fisher and Fisher, 2004).  Aggressive B cell lymphoma consists of precursor 
B-cell lymphoblastic leukaemia/lymphomas and peripheral B-cell lymphomas 
according the 4th edition of the World Health Organization Classification 
(WHO) of Haematopoietic and Lymphatic Tissues (Swerdlow et al., 2016). 
 
Diffuse large B-cell lymphoma (DLBCL) forms the majority of peripheral B-
cell lymphomas that also includes Blastic (blastoid/pleomorphic) mantle cell 
lymphoma, Burkitt’s lymphoma (BL) and High-grade B-cell lymphomas 
(HGBL) (Ott, 2017). DLBCL, not otherwise specified (NOS) are mainly nodal 
tumours exhibiting diffuse infiltration by medium-sized to large lymphocytes 
and do not conform to a specific subtype and/or variant. They can be sub-
categorised either by molecular subtype into germinal centre B-cell like 
(GCB-like) or activated B-cell like (ABC-like) or by morphology into 
centroblastic, immunoblastic and anaplastic (Alizadeh et al., 2000, 
Rosenwald et al., 2002).   
 
BL is a highly aggressive mature B-cell neoplasm that makes up 40 % of 
non- Hodgkin lymphomas in individuals under the age of 20. It defines three 
clinical variants: endemic, sporadic, and human immunodeficiency virus 
(HIV)-associated type. The endemic form is normally associated with 
Epstein-Barr virus (EBV) infection and commonly affects young children in 
Africa (Molyneux et al., 2012). The sporadic type is less geographically 
defined and common in children between 3 and 12 years of age and about 
30% of them are EBV-positive (Molyneux et al., 2012). Compared to the 
frequency in children and young adults, BL is rare in adults and mainly 
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associated with HIV (Aldoss et al., 2008). BL constitutes 1% to 2% of all non-
HIV adult lymphomas in Western Europe and the United States and accounts 
for 30% to 40% of HIV-associated non-Hodgkin lymphomas (Jaffe ES, 2001, 
Gabarre et al., 2001). BL is characterised by high rates of proliferation and 
apoptosis. The phagocytosis of apoptotic cells by macrophages leads to a 
“starry sky” appearance of haematoxylin and eosin (H&E) staining of 
histological sections of BL (Ford et al., 2015).   
  
The update of the WHO classification of 2016 introduced a new concept of 
HGBL to partly replace the previously so-called ‘grey zone’ lymphomas which 
show features intermediate between DLBCL and BL (Ott, 2017). HGBL 
comprises of two types: one harbours myc translocations and a bcl2 and/or a 
bcl6 rearrangement (HGBL Double Hit), the other lacks a double or triple hit 
constellation (HGBL, NOS) (Ott, 2017).  
 
1.1.2 Mechanism and treatment 
The common mechanisms underlying the pathogenesis of human B cell 
lymphoma include aberrant intracellular signalling, interrupted transcriptional 
and epigenetic regulation, and immune evasion (Ondrejka and Hsi, 2015, 
Shaffer et al., 2012).  
 
The molecular mechanisms employed by B cells for antibody diversification 
during V(D)J recombination, somatic hypermutation (SHM) and class switch 
recombination (CSR) all involve programmed DNA damage and thereby 
makes them susceptible to chromosomal translocations and oncogenic 
mutations (Nussenzweig and Nussenzweig, 2010, Lieber, 2016).  
 
Genomic translocations require DNA double strand breaks (DSBs) on 
separate chromosomes, proximity of broken ends and rearrangement 
between non-homologous chromosomes. DSBs during V(D)J recombination 
by recombinase-activating genes 1 and 2 (rag1 and rag2) in developing 
lymphocytes allows random rearrangement of H and L chains to generate the 
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B-cell receptors (BCR) (Lieber et al., 2006). These DSBs are repaired by 
non-homologous end joining (Nussenzweig and Nussenzweig, 2010).  In 
mature B cells, DSBs also occur during SHM and CSR inside the germinal 
centre (GC) in response to antigen encounter and they are initiated by the 
enzyme activation-induced cytidine deaminase (AID), a single strand DNA 
deaminase that mutates cytidine residues to uracyl (Di Noia and Neuberger, 
2007, Chaudhuri et al., 2007). AID functions at S regions and leads to CSR 
which changes the Ig isotype involving the Ig C region only whereas at V 
regions causes SHM that is responsible for BCR diversity (Robbiani et al., 
2008). In addition to non-homologous end joining (NHEJ), base-excision 
repair, mismatch repair and other mechanisms are necessary for accurate 
DSBs repair (Zhang et al., 2010). Dysregulation of repair pathways may 
facilitate B cell malignancy (Shaffer et al., 2002). 
 
Most B cell lymphoma require BCR expression as for normal B cell 
development (Shaffer et al., 2012). The BCR is formed by two identical 
heavy chain and two identical light chain immunoglobulin (Ig) polypeptides 
that are covalently linked by disulphide bridges. The type of B cell lymphoma 
is closely related to its proposed normal B-cell counterpart. The specific 
structures of BCR at distinct stages can be used to indicate the cellular origin 
of B cell lymphomas and related studies showing that most types of B-cell 
lymphoma are derived from GC or post-GC B cells (Kuppers et al., 1999, 
Stevenson et al., 2001). 
 
Chromosome translocation represents a hallmark of a plethora of aggressive 
B cell lymphomas (Kuppers and Dalla-Favera, 2001). Malignancy is caused 
by hijacking of normal B-cell signalling pathways to confer a survival or 
proliferative advantage. There are three main mechanisms through which 
this occurs. 
 
Firstly, translocating cis-regulatory transcriptional elements to the 
neighbourhood of a proto-oncogene and induced enhanced expression of the 
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oncogene. In terms of B cell lymphoma, these translocations often involve Ig 
loci. A prototypical example is BL where the profound oncogenic role of myc 
(also known as cmyc) and its translocation was initially identified.  BL result 
from the translocation of the myc proto-oncogene from 8q14 to 
immunoglobulin heavy-chain (Ig H) region (14q32) (80% of cases), or to the 
kappa light-chain gene (2p11) (15% of cases), or to the lambda-chain gene 
(22q11) leading to constitutive activation and subsequent accumulation of 
MYC (Hecht and Aster, 2000, Kuppers, 2005). The over-expression of MYC 
in BL is mainly caused by the translocation of myc that thereby deregulates 
and promotes cellular transformation through its effects on various cellular 
processes including proliferation, metabolism, differentiation and apoptosis.  
A small group (5–10% of phenotypically classical BL) may be fostered by 
deregulation of specific microRNA (Leucci et al., 2008). Deregulation of MYC 
is present in many other B cell cancers, such as plasmablastic lymphomas, 
multiple myeloma, rare mature B-cell lymphomas, transformed B-cell 
lymphomas and rare TdT-positive precursor B-cell lymphoblastic 
leukaemias/lymphomas. Myc translocation is also found in 5-10% of DLBCL 
and approximately 60% of these cases bear simultaneous rearrangements of 
bcl2 or/and bcl6 (Ott et al., 2013). GCB-type and ABC-type DLBCL present 
different incidences of myc rearrangement. Rearrangement of myc is present 
in up to 50% of grey zone’ lymphomas (Ott et al., 2013).  Secondly, the 
oncogenic activity is initiated by the expression of a chimeric protein 
produced by the fusion of two genes. For example, the bcr-abl fusion gene 
encodes a protein with deregulated kinase activity that has been detected in 
chronic myeloid leukaemia (CML) (Shaffer et al., 2012). Thirdly, 
chromosomal translocations can also cause structural and functional 
alterations in microRNAs that has been found in many cancers (Calin and 
Croce, 2007, Robbiani et al., 2009).   
 
Other transforming mechanisms, such as the anti-apoptotic nuclear factor of 
κB (NF-κB) pathway, ras signalling pathways, BCR-derived survival 
signalling, oncogenic mutations in myd88 are also involved in B cell 
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malignancy and perhaps the constitutive activation of the NF-κB signalling 
lies at the centre of these converged pathways by which B cell malignancies 
escape cell death (Kuppers, 2005, Gaidano et al., 1991, Martin-Subero et al., 
2002, Dierlamm et al., 1999, Shaffer et al., 2012).  NF-κB is a family of 
transcription factors that are formed by homo- and hetero-dimerization of the 
subunits p65 (encoded by rela), RelB, c-Rel, p50 (encoded by nfkb1), and 
p52 (encoded by nfkb2). NF-κB pathways can be activated by either classical 
or alternative mechanisms to initiate an anti-apoptotic transcriptional module, 
including the BCL2 family members BCL-XL and A1, c-FLIP, c-IAP1, c-IAP2, 
and other molecules (Grumont et al., 1999, Grumont et al., 1998, Gyrd-
Hansen et al., 2008, Gyrd-Hansen and Meier, 2010).  The activation of NF-
κB pathway and constitutive expression of various NF-κB target genes is a 
hallmark of ABC-like DLBCL (Davis et al., 2001).   
 
Certain viruses may also be related to B cell transformation. EBV has been 
found in 40% of cases of classical Hodgkin’s lymphoma and almost all 
endemic BL (Young and Rickinson, 2004). Herpes virus 8, a member of the 
herpes-virus family, is associated with the pathogenesis of primary effusion 
lymphomas (Cannon and Cesarman, 2000). 
 
Treatment of B cell lymphoma depends on the type and clinical stage of 
cancer. Currently, Rituximab, a chimaeric monoclonal antibody (MAb) for 
CD20, chemotherapy, and radiation have been widely used for the treatment 
of B cell lymphoma (Dotan et al., 2010). Combination of cyclophosphamide, 
doxorubicin, vincristine, and prednisone with Rituximab significantly improves 
the outcome for some patients (Hiddemann et al., 2005). 
 
1.1.3 Transgenic murine models of B cell lymphoma 
As reciprocal chromosomal translocations of the immunoglobulin loci and a 
proto-oncogene is a hallmark of many types of aggressive B cell lymphoma, 
murine transgenic models of B cell lymphoma are established by the strategy 
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of translocation of the oncogene to a site downstream of a B-cell specific 
enhancer or promoter region (Kuppers and Dalla-Favera, 2001).   
Brief introduction of myc and its roles in cancer 
Cmyc (also called myc here) belongs to a family of encoding transcription 
factors, which also includes nmyc and lmyc genes. These three genes are 
expressed differently during development and among them myc has drawn 
intense interest (Meyer and Penn, 2008, Zimmerman and Alt, 1990, Brodeur 
et al., 1984).  
 
By binding the carboxy-terminal basic-helix–loop–helix–zipper domain of 
MAX, the formation of MYC–MAX heterodimers activates many genes 
through binding enhancer box sequence of 5′-CACGTG-3′which is a 
universal occurring DNA-binding motif in the human genome (Luscher, 
2001). Recent data also demonstrate that MYC–MAX heterodimers may also 
suppress gene expression (Staller et al., 2001, Herold et al., 2002). It is 
widely accepted that myc activity mainly relies on the deregulated and 
constitutive activation of its various target genes through its regulation of 
transcription. The wide array of transcriptional targets of myc indicates its 
complicated and broad biological functions. 
 
Myc has revealed its role in various cellular outcomes including modulating 
the cell cycle and differentiation (for example, active MYC promotes G0/G1 
to S phase progression, regulates the function of cyclin-dependent kinase 
(CDK) inhibitors), promotes cell growth (increase cell metabolism and protein 
synthesis), increases genomic instability (gene amplification, chromosomal 
instability) (Roussel et al., 1991, Oster et al., 2002, Facchini and Penn, 1998, 
de Alboran et al., 2001, Trumpp et al., 2001, Obaya et al., 1999, Li and 
Dang, 1999, Schmidt, 2004, Felsher and Bishop, 1999b). Since the late 
1990s, myc has been found to promote angiogenesis (Ngo et al., 2000, 
Dews et al., 2006, Watnick et al., 2013, Soucek et al., 2007).  
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In 1992, Gerard Evan and his colleagues revealed an intriguing finding that 
despite its well-known role in cell proliferation, myc induces substantial 
apoptosis in Rat-1 fibroblasts (Evan et al., 1992). Since then, several studies 
demonstrate that the over-expression of MYC can sensitise cells to undergo 
apoptosis (Pelengaris et al., 2002a, Pelengaris et al., 2002b, Shi et al., 1992, 
Meyer et al., 2006). Direct evidence for the crucial role of myc in apoptosis 
was that myc -null cells are resistant to many apoptotic stimuli (Soucie et al., 
2001).  
 
There is also indirect evidence that apoptosis suppresses the role of myc by 
revealing the close collaboration between myc and pathways underlying 
apoptosis. For example, over-expression of anti-apoptotic proteins such as 
BCL2 or BCL-XL, or loss of the tumour suppressors ARF or p53 have shown 
strong correlation with myc in several mouse models (Strasser et al., 1990, 
Adams et al., 1985, Blyth et al., 1995, Elson et al., 1995, Jacobs et al., 1999, 
Eischen et al., 1999). The possible mechanisms underlying myc induced 
apoptosis include the direct regulation of cell cycle and indirect actions 
caused by DNA damage. Specifically, myc activates the pro-apoptotic 
molecule BAX by either direct chromatin remodelling of BAX or through 
activation of the p53 via ARF, leading to transcription of BAX. In an in vitro 
setting, MYC seems to accumulate reactive oxygen species (ROS) via E2F1-
mediated inhibition of NF-κB and whether the cell commits to apoptosis or 
growth arrest is likely to depend on the cell type (Tanaka et al., 2002, Vafa et 
al., 2002). Apparently, the interactions that are associated with MYC and 
apoptosis are complex and depend on the cell type as well as the tissue 
location and the involvement of additional mutations in other pro- and anti-
apoptotic genes. 
 
A very recent study shows that MYC is a key regulator of the proliferation 
program of T and B lymphocytes (Heinzel et al., 2017). Heinzel et al. reveal 
that MYC expression is tightly controlled by the signals received 
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quantitatively, which controls the extent of lymphocyte proliferation, at least in 
this mouse system in vitro.  
 
In terms of tumour biology, deregulated MYC expression is usually 
associated with aggressive, poorly differentiated tumours as well as poor 
prognosis.  Many studies illustrate the pervasive role of myc in the genesis of 
tumours. Several transgenic mouse models demonstrate that deregulated 
expression of MYC is sufficient to initiate tumourigenesis (Adams et al., 
1985, Morton and Sansom, 2013). However, in each of these models, the 
time delay before the onset of tumours and the accelerated rates of tumour 
formation with the existence of other genetic alterations indicates that other 
co-operative mutagenic alterations are required to enable tumour formation. 
The transgenic mice bearing both abnormal myc and bcl2 carry higher 
potential for lymphomagenesis compared with mice with ectopic MYC 
expression only (Strasser et al., 1990, Adams et al., 1985). Mouse models 
also show that myc acts in synergy with p53 and arf to enhance 
lymphomagenesis (Blyth et al., 1995, Elson et al., 1995, Tago et al., 2015). 
The exact mechanisms underlying these are still unknown and the most 
plausible explanation is that MYC induced apoptosis is inhibited. 
 
In inducible transgenic models where mice have ectopic MYC expression in 
a spatio-temporal manner tumours in T cells, B cells, liver and bone can be 
regulated and indicate the importance of myc in tumour maintenance 
(Felsher and Bishop, 1999a, Morton and Sansom, 2013).  
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Figure 1.1 Myc-induced tumour initiation and maintenance 
Myc induces tumourigenesis by orchestrating with several tumor-suppressing 
checkpoint mechanisms, including proliferative arrest, apoptosis, and/or 
senescence. The suppression of MYC was shown to sustain tumour 
regression (adopted from (Gabay et al., 2014)). 
 
In addition to cell-autonomous function underling myc oncogenesis, myc may 
also regulate immune surveillance pathways to foster tumourigenesis (Gabay 
et al., 2014, Grivennikov et al., 2010, Rooney et al., 1985). MYC suppression 
provokes tumour regression with reduced kinetics in an 
immunocompromised RAG1-/- host (deficient for B and T cells) or a CD4-/- 
host (deficient for CD4+ T-helper cells) (Rakhra et al., 2010). 
Mouse B cell lymphoma models 
Due to the evident critical roles of myc in B cell lymphoma, there are several 
transgenic murine models mimicking human B cell lymphoma by 
manipulating myc. 
  
In the Eµ- myc model, generated by linking the myc gene to the Igh enhancer 
(Eµ), two principal tumour phenotypes develop, one resembling BL which 
arises during an early time window and another form resembling DLBCL 
which develops after day 400 (Kitaguchi et al., 2009, Sander et al., 2012, 
Adams et al., 1985). Introducing retroviruses expressing the ras oncogene 
into this model leads to an accelerated lymphomagenesis (Kitaguchi et al., 
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2009). By crossing the Eµ-myc mice with transgenic mice bearing a BCR 
specific for hen egg lysozyme, the BCR was shown to cooperate with the 
over-expression of MYC to produce more aggressive lymphomas of mature 
B cell origin in the Eµ-myc /BCRHEL mice (Junttila and de Sauvage, 2013).  
This supports the notion that BCR-derived survival signaling can facilitate the 
evolution of B cell lymphoma. 
 
The introduction of a transgene encoding soluble hen egg lysosyme (sHEL) 
in Eµ-myc/BCRHEL mouse leads to development of more aggressive tumors 
composed of activated mature post–GC–like B cells, closely resembling BL. 
The disruption of BCR signaling in both Eµ-myc/BCRHEL mouse and Eµ-
myc/BCRHEL/sHEL mice indicates the importance of BCR expression for 
tumour maintenance and development (Young et al., 2009). One of the BCR-
derived signal effectors is spleen tyrosine kinase (SYK), a non-receptor 
tyrosine kinase. Activation of SYK can support cell survival and proliferation 
by pathways involving the cooperation of NF-κB, PI3K, NF-AT, MAP kinase, 
and RAS signaling (Rowley et al., 1995, Dal Porto et al., 2004). SYK 
exhibited a role for survival of non-Hodgkin lymphoma-like tumours in the Eµ-
myc/BCRHEL/sHEL mouse and suggests it to be an attractive therapeutic 
target (Carter et al., 2018). 
 
Although human follicular lymphomas over-express the anti-apoptotic 
oncogene bcl2 by chromosomal translocation of bcl2 under the control of Ig 
H, transgenic mice (Eµ-bcl2) expressing BCL2 by Eµ do not develop follicular 
lymphoma.  VavP-bcl2 mice bearing a bcl2 transgene controlled by Vav gene 
regulatory sequences (VavP), engineered to over-express BCL2 in cells of all 
hematopoietic lineages develop follicular lymphoma when mice are older 
than 10 months and this may be promoted by the prolonged GC reactions 
dependent on CD4 T-cell help (Egle et al., 2004). 
 
More recent studies have indicated that at least two pathways-MYC and 
PI3K-are required to establish the full BL phenotype and next generation 
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sequencing results reveal mutations in tcf3 or id3 genes which are crucial in 
the PI3K pathway (Sander et al., 2012, Davis et al., 2001, Rowley et al., 
1995).  
 
Other mechanisms underlying the cell proliferation also show oncogenic 
potential.   For example, transgenic mice (Eµ-brd2) with lymphoid-restricted 
overexpression of a nuclear-localized transcription factor kinase, double 
bromodomain protein bromodomain-containing 2 (BRD2) develop splenic B-
cell lymphoma (Greenwald et al., 2004). Constitutive expression of BRD2 
increases cell proliferation through the transcription of cyclin A (Greenwald et 
al., 2004). 
 
1.2 Tumour microenvironment 
It is widely accepted that a tumour, rather than being a collection of 
homogeneous deviant cells, is actually a community comprising malignant 
cells together with stromal components including macrophages, fibroblasts, 
epithelial cells, endothelial cells (both blood and lymphatic), neutrophils, T 
cells, B cells and mast cells (Hanahan and Weinberg, 2000). 
 
The interactions among these cells including tumour cell-stromal cells and 
stromal cells-stromal cells provide a tumour microenvironment (TME) to 
favour tumour growth. The concept that TME is evolving with the cancer cell 
and both continuously participate in the process of tumourigenesis is now 
acknowledged. The presence of infiltrating immune cells, angiogenic 
endothelial cells, cancer-associated fibroblasts, as well as a variety of 
cytokines, chemokines, growth factors, and proteinases is crucial for tumour 
cell proliferation, invasion and metastasis. The TEM is also involved in 




Among these cancer-promoting stromal elements, the macrophages are an 
intensively studied candidate and the relatively newly emerging candidate, 
the extracellular vesicles (EVs) will be discussed in detail (Carter et al., 2018). 
 
1.2.1 Macrophages 
Macrophages are professional phagocytes and are widely present in 
cancers. The accumulation of macrophages is achieved by monocyte 
recruitment as well as tissue macrophage proliferation (Jenkins et al., 2011, 
Mantovani et al., 2011, Hashimoto et al., 2013). Recent studies show that the 
resident macrophages emanated from yolk sac-derived progenitors and the 
macrophages responsible for the pathogenesis seem to arise from circulating 
bone marrow derived monocytes (Lavin et al., 2015, Noy and Pollard, 2014). 
 
The phenotypic plasticity of macrophages allows them to execute various 
functions by acquiring a spectrum of phenotypes depending on 
environmental signals (Lewis and Pollard, 2006, Hanahan and Coussens, 
2012, Sica et al., 2008, Mosser and Edwards, 2008, Qian and Pollard, 2010). 
 
A relatively large body of work has even devoted to understanding the exact 
mechanisms of macrophage activation and polarisation and remains to be 
fully understood. Traditionally macrophages could be classified as either 
classically activated, also known as M1, or alternatively activated, M2. 
According to established definitions, the M1 activation state is induced by 
interferon gamma (IFN-γ) and lipopolysaccharide (LPS) stimulation, and M2 
is activated by IL-4 and IL-13 (Mantovani et al., 2002). M1 classically 
activated macrophages express high levels of IL12 and IL23 and exert pro-
inflammatory, anti-proliferative and cytotoxic functions by producing effector 
molecules, such as ROS/RNS and inflammatory cytokines, participating as 
inducers and effector cells in Th1 responses. The M2 macrophages express 
high levels of IL10 and scavenger receptors, such as CD163 and CD 206. 
They clear debris, promote wound healing, angiogenesis, tissue remodelling 
and repair (Kreider et al., 2007, Mantovani et al., 2002).  However, the 
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macrophage M1 and M2 phenotype classification is an oversimplification and 
does not accurately represent the full spectrum of macrophages activation 
states. 
 
The term, tumour-associated macrophages (TAMs), describes the 
macrophages that accumulate in both primary and secondary tumours. They 
are activated by signals such as lymphotactin, IL10 and antibodies in the 
TME and normally resemble alternatively activated macrophages (Sica et al., 
2008, Wynn et al., 2013). High infiltration of TAMs has been associated with 
poor prognosis in over 80% of human tumours, with the notable exception of 
colorectal adenocarcinoma (Tsutsui et al., 2005, Cavnar et al., 2017) 
 
As an abundant component of solid and haematological tumours, TAMs are 
thought to contribute to tumour growth at various stages including 
angiogenesis, invasion and metastasis by promoting an anti-inflammatory, 
immune-suppression, pro-tumourigenesis microenvironment (Martinez et al., 
2009, Qian and Pollard, 2010, Cook and Hagemann, 2013, Hanahan and 
Coussens, 2012). Indeed, many clinical observations and macrophage 
depletion experiments in animal models have shown the trophic role of TAM 
in tumour angiogenesis.  
 
Angiogenesis is the process of blood vessel formation from existing vessels 
which is distinguished from the process called vasculogenesis defining the 
de novo formation of vessels dependent on angioblasts (Carmeliet and Jain, 
2000). Angiogenesis is tightly regulated by several signalling molecules such 
as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), 
basic FGF (bFGF), platelet-derived growth factor (PDGF), placenta growth 
factor (PGF), transforming growth factor (TGF)-α, TGF-β, hepatocyte growth 
factor or scatter factor (HGF or SF), tumour necrosis factor-α (TNFα), 
angiogenin, interleukin-8 (IL-8), as well as angiopoietins (Gacche and 
Meshram, 2014, Yancopoulos et al., 2000).  The receptors on endothelial 
cells sense the correspondent molecules and start the angiogenic process 
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involving sprouting, branching, artery and vein differentiation and lumen 
formation (Ferrara et al., 2003). There are two potential mechanisms 
underlying angiogenic vessel formation: sprouting and intussusceptive 
angiogenesis. Sprouting angiogenesis is the predominant mechanism and 
has been well described. This starts with the migration of endothelial cells at 
the leading edge, named ‘tip’ cells, with the help of metalloproteases (MMPs) 
degrading of surrounding extracellular matrix (ECM). It is followed by the 
extension of filopodia which lead to the duplication of  ‘stalk’ cells to create 
the lumen of the forming vessel (Gerhardt et al., 2003).  Intussusceptive 
angiogenesis, firstly introduced by Caduff et al., in 1986 and then renamed 
by Burri and Tarek in 1990, is a rare alternative form of angiogenesis which 
has yet to be observed in zebrafish (Caduff et al., 1986, Burri and Tarek, 
1990, Schuermann et al., 2014, Makanya et al., 2009).  Intussusceptive 
angiogenesis defines the process where an existing vessel divides into two 
by vessel intraluminal growth rather than endothelial cell proliferation (Caduff 
et al., 1986, Burri and Tarek, 1990, Hlushchuk et al., 2011).  
 
Tumour angiogenesis - the generation of a pro-tumour vascular system from 
pre-existing blood vessels - is essential for tumour growth beyond a 
microscopic size of 1 to 2 mm3 and also is considered to serve as a route for 
tumour metastasis (Arnold, 1985, Fox et al., 1996, McDonnell et al., 2000). In 
the tumour microenvironment, the balance between endogenous 
angiogenesis inhibitors and stimuli is disturbed by various signals including 
growth factors, proteases and ECM components. These signals are 
produced by neoplastic cells themselves as well as several stromal cell types 
including fibroblasts, smooth muscle cells/pericytes and macrophages, which 
are recruited by tumour cells, in close proximity to the blood vessels 
(Watnick, 2012, Ribatti and Crivellato, 2012). 
 
 It is well documented that tumours are infiltrated by immune cells which in 
turn are dependent on angiogenesis (Ribatti and Crivellato, 2009).  Most, if 
not all types of immune cells elicit their angiogenesis-modulating functions 
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through the production and release of a large spectrum of pro-angiogenic 
mediators including angiogenic factors, extracellular matrix proteins, 
adhesion receptors, and proteolytic enzymes (Ribatti and Crivellato, 2009, 
Tazzyman et al., 2009). Among all inducers or regulators of angiogenesis, 
either cells or cell products, the macrophage is considered a major 
protagonist. Commitment of macrophage to a pro-angiogenic phenotype 
gives rise to pro-angiogenic cytokines and growth factors including VEGF, 
TNFα, IL-8 and FGF-2 and CSF-1/M-CSF as well as enzymes, such as 
MMP-2, -7, -9, -12, and cycloxygenase-2 (COX-2) (Sunderkotter et al., 1991, 
Lewis et al., 1995, Klimp et al., 2001).  Normally TNFα is considered as a key 
feature of M1 macrophages and has been associated with higher endothelial 
permeability in a 3D tumour-endothelial intravasation microfluidic-based 
model (Zervantonakis et al., 2012). In a transgenic zebrafish model 
(Tg(mpeg1::mCherry/tnfα::eGFP)) genetically engineered to exhibit mCherry-
labeled macrophages and eGFP-labelled TNFα, RT-qPCR on Fluorescence 
Activated Cell Sorting (FACS)-sorted TNFα+ and TNFα- macrophages 
showed that they, respectively, expressed M1 and M2 mammalian markers. 
Furthermore, fate tracing of TNFα+ macrophages during the time-course of 
inflammation caused by wounds or bacterial infection demonstrated that M1 
macrophages progressively converted into M2-like phenotype during the 
resolution step (Nguyen-Chi et al., 2015). 
 
TAMs are attracted to the hypoxic niche in TEM and polarised to a M2 type 
producing VEGF (Newman and Hughes, 2012). TAMs function as the "bridge 
cells" to promote vascular anastomosis and sprouting (Lewis and Pollard, 
2006). Furthermore, a sub-population of monocytes/macrophages 
expressing the angiopoietin receptor Tie-2 is a critical inducer of 
angiogenesis (De Palma et al., 2005).  Angiopoietin-2 (ANG-2)/TIE-2 
signalling in TEMs upregulates proangiogenic genes and augments their 
inherent proangiogenic functions (Coffelt et al., 2010). Macrophages also 
secrete WNT whose receptors include FZD1, FZD2, FZD4, FZD5, FZD6, 
FZD7, FZD9, FZD10, LRP5, LRP6 are widely expressed in endothelial cells 
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(Goodwin et al., 2006, Favre et al., 2003, Mao et al., 2000). Wnt1, Wnt3a and 
Wnt5a have been related to two key events in angiogenesis, endothelial cell 
proliferation as well as migration in some situations (Masckauchan et al., 
2005, Cheng et al., 2008, Newman and Hughes, 2012).  WNT5a may also be 
involved in regulating TIE-2 expression in macrophages (Masckauchan et al., 
2006).  
 
Lymphangiogenesis and angiogenesis are closely related but unlike 
angiogenesis, not all solid tumours induce intratumoural lymphangiogenesis. 
Certain types of solid tumour including breast cancer, colorectal cancer, and 
head and neck cancer develop lymphatic vessels and the exact function of 
lymphangiogenesis in promoting tumour growth has yet to be fully 
understood (Al-Rawi et al., 2005, Cao, 2005). The most well recognised role 
of lymphangiogenesis is as an important conduit for the metastatic spread of 
human cancer (Al-Rawi et al., 2005). There is a growing appreciation that the 
VEGF-C/ VEGF-D/VEGFR-3 signalling system is a key regulator of tumour 
lymphangiogenesis (Yonemura et al., 2005, Adams and Alitalo, 2007). 
The mechanisms underlying the close relationship between TAMs and 
metastasis lies in epithelial-to-mesenchymal transition and promotion of 
tumour cell extravasation to the circulation. TAMs also facilitate the 
extravasation, survival, and persistent growth of metastatic cells and provide 
premetastatic niches (Lewis et al., 2016). The requirement for 
CCR2+VEGFR1+Ly6C-F4/80+ metastasis-associated macrophages (MAM) 
was demonstrated in lung cancer (Colegio et al., 2014). The involvement of 
VEGF receptor VEGFR1 on MAMs also facilitates metastasis in breast 
cancer (Qian et al., 2015).  
Their immunosuppressive function is another dominant feature of TAMs in 
the TME. TAMs can directly express molecules such as IL10, TGFb, 
activated STAT3, and arginase-1 or through the suppression of NK cells and 
T cells to enhance immune escape (Ruffell and Coussens, 2015, Lewis and 
Pollard, 2006). The subfamily of receptor protein tyrosines-Tyro3, Axl, and 
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Mer, as key pleiotropic inhibitors of the immune system, has revealed crucial 
functions in immune regulation of cancer development and been positively 
associated with cancer (Rothlin et al., 2015, Paolino and Penninger, 2016).  
The ligands of Tyro3, Axl, and Mer include growth arrest-specific gene 6 
(Gas6), Protein S (Pros 1), Tubby, tubby-like protein 1 (Tulp-1) and Galectin-
3 (Stitt et al., 1995, Caberoy et al., 2010, Caberoy et al., 2012).  Although 
signalling pathways of Tyro3, Axl, and Mer have been shown to exert a 
crucial pro-oncogenic role in the initiation and progression of human cancers 
and their roles in immune-regulation have been extensively revealed, their 
direct immune regulation in TEM has yet to be further explored (Rothlin et al., 
2007, Whitman et al., 2014, Ben-Batalla et al., 2013). The first study 
indicating the anti-tumour immunity of Tyro3, Axl, and Mer signally pathway 
used Gas-6-deficient mice where the tumour proliferation and metastasis 
were significantly impaired in different experimental cancer models by 
inhibition of Gas6 in hematopoietic cells (Loges et al., 2010). This study also 
showed that tumour cells educated infiltrated TAMs to produce Gas6 and 
may serve as an additional mechanism by which tumour cells modulate TEM 
for their own benefit (Loges et al., 2010). In the Mer-deficient mice, several 
cancers including breast cancer, melanoma and colon cancer exhibited 
prolonged latency and decreased metastasis (Cook et al., 2013). 
Furthermore, Mer-deficient leukocytes confer tumor resistance to Mer+/+ 
mice and their anti-tumour role was confirmed by bone marrow transplants 
(Cook et al., 2013). NK cells have recently been shown to be recruited 
through Tyro3, Axl, and Mer signaling pathways leading to anti-metastasis 
functions in TEM (Paolino et al., 2014). 
 
1.2.2 Extracellular vesicles (EVs)  
The term extracellular vesicles (EVs) is used to describe a highly 
heterogeneous group of cell-derived membranous structures (van Niel et al., 
2018). Although the nomenclature in the literature remains rather vague: 
many different names are used to refer to their origin (e.g. from prostate 
gland epithelial cells: prostasomes, from tumour cells: oncosomes), size 
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(prefix micro or nano:  microvesicles, nanovesicles) and proposed functions 
(calcifying matrix vesicles, argosomes, tolerosomes) (Gould and Raposo, 
2013). EVs may be broadly classified into exosomes and microvesicles 
(MVs) based on current knowledge of their cellular origin (Raposo and 
Stoorvogel, 2013, Akers et al., 2013, Todorova et al., 2017, van Niel et al., 
2018).  
 
Exosomes (40 to 120nm in diameter) are intraluminal vesicles of endocytic 
origin formed by inward budding of endosomal membrane and secreted upon 
fusion of multivesicular endosomes with the cell surface (Harding et al., 
1984, Pan et al., 1985). Their endocytic origin enriches them with endosome-
associated proteins such as Rab GTPases, SNAREs, Annexins, and flotillin 
as well as some membrane protein such as CD63, CD81, and CD9 (Shao et 
al., 2018). Initially exosomes were reported to be released by B lymphocytes 
and dendritic cells and mainly involved in immune regulation (Raposo et al., 
1996, Zitvogel et al., 1998). Now exosomes are considered to be secreted by 
various cell types and have been widely implicated in intercellular 
communication (Colombo et al., 2014). MVs (50 to 1000nm in diameter) are 
formed by direct outward budding from the plasma membrane and 
subsequent release into the extracellular space (Tricarico et al., 2017, 
Colombo et al., 2014).  The components of MVs are selectively enriched with 
protein and nucleic acid cargos and closely related to the cell types, 
physiological context and a wide variety of extracellular stimuli (Tricarico et 
al., 2017).  
  
Of note, the reported morphology and the functional properties of EVs are 
based on methods of isolation and analysis. EVs appear as artefactual cup-
shaped morphology probably caused by the processing of conventional 
transmission electron microscopy (TEM) and they are demonstrated as 
round structures enclosed by double-leaflet membranes by cryo-electron 
microscopy (cryo-EM) (Shao et al., 2018, Conde-Vancells et al., 2008). 
Although it is widely acknowledged that, the biogenesis of EVs is highly 
regulated and finely tuned, which equips EVs with particular bioactive 
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molecules including proteins, lipids, DNA, mRNA and miRNA (Colombo et 
al., 2014). The current available techniques for separating EVs result in a 
heterogeneous population of vesicles of unknown origin and the limited 
characterisation protocols precludes a clear attribution of a particular function 
to the different types of secreted vesicles and may account for the 
contradictions in different studies (Willms et al., 2016). 
 
Abundant clinical observations show that release of EVs is increased in 
cancer and many studies suggest their complex role in pathogenesis ever 
since their biological significance was appreciated (Inal et al., 2012, 
Whiteside, 2005, Carter et al., 2018).  EVs have shown the potential to carry 
biomarkers for cancer diagnosis and prognosis (Soekmadji et al., 2017a, 
Song et al., 2017, Matsuzaki and Ochiya, 2017). EVs can also facilitate 
immune escape and cause drug resistance in some cancers (Samuel et al., 
2017, Soekmadji et al., 2017b, Czernek and Duchler, 2017).  
 
EVs contains various cargoes, such as DNA, mRNA, microRNA, growth 
factors, adhesion proteins, lipids, tissue factors and protease inhibitors, 
based upon their cell origin and biogenesis pathways (Inal et al., 2012, 
Redzic et al., 2013, Collier et al., 2013, Bern, 2017, Chen et al., 2014, 
Williams et al., 2014, Zomer et al., 2010). Considering their small size and 
ability to carry selective cargo it seems likely that EVs spread the effects of 
their parental cells to distal sites (Vader et al., 2014, Pap et al., 2009). In 
ovarian cancer, EVs from malignant cancers selectively packaged MMP1 
mRNA and enhanced the destruction of the peritoneal mesothelium barrier 
(Yokoi et al., 2017). Moreover the MMP1 mRNA transferred into mesothelial 
cells causes increased apoptosis of recipient cells(Yokoi et al., 2017). 
Galectins are enriched in EVs from different cancers, which may be 
important for the uptake of EVs by recipient cells (Escrevente et al., 2011, 
Mathivanan et al., 2010, Batista et al., 2011, Welton et al., 2010, Choi et al., 
2011, Barres et al., 2010). EVs also show an ability to regulate the 
phenotype of macrophages in colorectal cancer (Shinohara et al., 2017).  
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Among their various activities in tumours, the involvement of EVs in 
angiogenesis has been drawing increasing attention. EV-associated Delta-
like 4 was transferred from tumour cells and may induce angiogenic 
sprouting by altering the Notch signaling pathway (Noguera-Troise et al., 
2006, Sheldon et al., 2010). In addition to delivering angiogeneic molecules, 
much evidence indicates that miRNA plays an important role in the EV-
induced tumour angiogenesis. Hypoxia-cued EVs from multiple myeloma 
cells were shown to accelerate angiogenesis by targeting the FIH-1/HIF-1 
signalling pathway via miR-135b (Umezu et al., 2014). EVs from lung cancer 
cells appeared to promote angiogenesis through miR-23a/PTEN 
(phosphatase and tensin homologue on chromosome ten) pathway and their 
effect was enhanced when the cells were X-ray treated (Zheng et al., 2017).  
EVs released from cancer cells were shown to contain miR-9 and activate 
the JAK/STAT pathway leading to endothelial cell migration and tumour 
angiogenesis (Zhuang et al., 2012).  
 
Hypoxia drives the release of EVs to induce angiogenesis (Wang et al., 
2014). PH also appears to be a regulator of the lipid composition of EV 
(Parolini et al., 2009). Besides these exogenous stimuli, endogenous factors 
such as TSAP6 (cellular stress-regulated protein) shown to enhance EVs 
production (Yu et al., 2006), oncogene erbb2/her2 altered the cargo of EVs in 
favour of oncogenic effects (Amorim et al., 2014) . Abundant studies show 
that the molecular signature characteristic of their cell of origin is highly 
modulated by the stimulus suggesting that activation regulates the non-
uniform distribution of various contents compared to the parental cells and to 
be closely associated with function. 
 
Apoptosis and endothelial cell sprouting are closely associated (Li et al., 
2014). While intensive investigation has targeted the role of EVs in cancer, 
apoptosis induced EVs remained less explored. Tumour cells release more 
EVs during apoptosis. These EVs are released at different stage of apoptosis 
compared to apoptotic bodies and exhibit different size profiles. We define 
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the EVs from apoptotic tumour cells whose productions are proportional to 
the degree of apoptosis as Apo-EVs. The most obvious way to distinguish 
Apo-EVs and apoptotic bodies is dependent on their sizes: Apo-EVs being 
less than 1 micron and apoptotic bodies ranging from 1 to several microns in 
diameter (Atkin-Smith and Poon, 2017, Gregory and Paterson, 2018). 
Obviously, this difference in size is insufficient for a clear distinction and the 
components of EVs are also used as comparison standards with EVs 
containing integral plasma membrane proteins, enzyme systems and RNAs 
while apoptotic bodies harbour organelles and nuclear components including 
DNA and histones (Gregory and Paterson, 2018).  Apo-EVs were shown to 
contain higher levels of B cell surface markers (CD19 and CD20), apoptosis 
associated proteins, DNA and RNA than EVs from viable tumour cells 
(Patience, 2016).  Furthermore, the presence of matrix metalloproteinases, 
MMP2 and MMP12 in Apo-EVs indicates a role in angiogenesis (Patience, 
2016). Apo-EVs possess pro-angiogenic properties in the in vitro human 
umbilical vein endothelial cell (HUVEC) angiogenesis assay (Patience, 
2016). As mentioned before, the separation and characterisation methods 
are crucial for EV study. The most widely used method for the isolation of EV 
is differential ultracentrifugation and this is indeed the main principle for the 
protocol used for the Apo-EVs separation in previous studies by our group.  
The limitations of separation protocols of EVs through differential 
ultracentrifugation include the contamination by many factors, such as cells 
and disruption of the membrane structure of EVs. 
 
1.3 Apoptosis 
1.3.1 Characteristics and mechanisms 
The term, apoptosis was introduced by Kerr et al. to describe a controlled 
way of cell death morphologically characterised by nuclear fragmentation, 
chromatin condensation, cell shrinkage, cytoplasmic acidophilia and release 
of apoptotic bodies by budding (Kerr et al., 1972, Kerr, 2002). This form of 
programmed cell death plays vital roles in normal development and 
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homeostasis including normal cell turn over, immune reactions (Green, 
2011).  Dysregulation of apoptosis is responsible for many disease states 
including autoimmune disorders, neurodegenerative diseases, ischemic 
damage and cancers (Mattson, 2000, Nagata, 2010, Hanahan and 
Weinberg, 2011). 
 
The mechanisms driving the fate of apoptotic cells are mainly divided into 
two circuits: the extrinsic or death receptor pathway and the intrinsic or 
mitochondrial pathway (Ichim and Tait, 2016).  There is an additional 
perforin/granzyme pathway involving T cell mediated cytotoxicity and 
activates apoptosis by either granzyme A or granzyme B in a perforin-
granzyme-dependent manner (Chowdhury and Lieberman, 2008).   
 
The intrinsic pathway, which is often deregulated in cancer, is initiated by a 
wide array of stress inside the cell, such as DNA damage, cytokine/nutrient 
deprivation, endoplasmic reticulum stress or virus infection (Ichim and Tait, 
2016). B-cell lymphoma-2 (BCL-2) family proteins lie at the heart of 
regulating the intrinsic pathway. The BCL-2 family is formed of two groups: 1) 
pro-apoptotic proteins, such as Bax, Bak, together with Bcl-2-homology (BH)-
3-only proteins Bid, Bad, and Bim, and 2) anti-apoptotic proteins Bcl-2, Bcl-x, 
Bcl-XL, Bcl-XS, Bcl-w, and BAG (Moldoveanu et al., 2013, Youle and 
Strasser, 2008). These proteins control the mitochondrial outer membrane 
permeabilisation (MOMP) and consequently the release of pro-apoptotic 
factors including cytochrome c, AIF and SMAC/DIABLO (Liu et al., 1996). 
Cytochrome c, considered as a most important regulator of apoptosis, is 
released into the cytosol, where it interacts with apoptosis protease-
activating factor-1 (Apaf-1), deoxyadenosine triphosphate (dATP), and pro-
caspase-9 to form a caspase-activating complex called the apoptosome 
(Acehan et al., 2002).  The apoptosome activates caspase-9 which ultimately 
activates effector caspases (caspase-3, 6 and 7) (Taylor et al., 2008). 
 
 23 
The extrinsic pathway is mediated by transmembrane receptor-mediated 
interactions involving the death receptors of the TNF superfamily including 
TNFR, Fas and tumour necrosis factor-related apoptosis-inducing ligand 
(TRAIL).  Upon binding of extracellular ligands (such as FasL and TNFα) to 
death receptors, the cytoplasmic domains of the receptors, so called ‘death 
domains’ attract adaptor proteins such as Fas-associated death domain 
protein (FADD) (Ashkenazi and Dixit, 1998).  This leads to the formation of 
the death-inducing signalling complex (DISC) resulting in the accumulation 
and activation of caspase-8, an initiator caspase which triggers the execution 
phase of apoptosis (Kischkel et al., 1995, Wajant, 2002, Creagh et al., 2003).   
 
Perforin/granzyme pathways are mainly used by cytotoxic T cells and NK 
cells to kill target cells (Creagh et al., 2003, Brunner et al., 2003). Cytotoxic T 
cells exert their cytotoxic effects on target cells by secretion of perforin, a 
pore-forming protein, leading to the transmission of cytoplasmic granules 
containing granzyme A and granzyme B into the target cells (Trapani and 
Smyth, 2002). Granzyme A induces apoptosis by a caspase-independent 
mechanism by inducing DNA degradation (Fan et al., 2003, Lieberman and 
Fan, 2003). Granzyme B, can activate caspase-10, caspase-3, cleavage of 
ICAD (Inhibitor of Caspase Activated DNAse), and utilize the mitochondrial 
pathway, thereby triggering apoptosis (Sakahira et al., 1998, Sakahira et al., 
2015, Barry and Bleackley, 2002, Russell and Ley, 2002).   
 
The extrinsic pathway, intrinsic pathway and Perforin/granzyme B pathways 
converge on the execution phase. Initially synthesized as inactive pro-
caspases, initiator caspases (caspase 8 and 9) gain catalytic activity in 
response to apoptosome stimuli, death receptors and granzyme B (Riedl and 
Shi, 2004). Initiator caspases activate executioner caspases (caspase 3, 6, 
and 7) (Riedl and Shi, 2004). Once activated, a single executioner caspase 
can cleave and activate other executioner caspases, leading to a cascade of 
catalytic activation (McIlwain et al., 2015). Effector caspases activate 
cleavage of various substrates that lead to the characteristic biochemical 
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changes causing the final destruction of cells (Hengartner, 2000, Elmore, 
2007).  
 
1.3.2 Apoptotic cell clearance 
Apoptotic cells are normally cleared quickly and most of them are found 
within phagocytic cells in vivo (Kerr et al., 1972, Schrijvers et al., 2005).  The 
clearance and phagocytosis of dying cells have been shown to achieved by 
neighbouring ‘non-professional’ phagocytes of various lineages including 
fibroblasts, epithelial cells, mesenchymal cells, as well as professional 
phagocytes, especially macrophages (Hall et al., 1994, Juncadella et al., 
2013, Wood et al., 2000, Gregory and Pound, 2010).  Many pathways have 
been descried in the process of clearance of apoptotic and three phases of 
‘recognition, response and removal’ have been rationalized (Gregory and 
Pound, 2010).  
 
Clearance of apoptotic cells is initiated by the ‘recognition’ of phagocytes 
through the release of ‘find me’ signals (Gregory and Pound, 2010). These 
‘find me’ signals released from apoptotic cells provide a chemotactic gradient 
that attract the phagocytes to the apoptotic cell (Gregory and Pound, 2010). 
The chemotactic factors include lipids Sphingosine-1-phosphate (S1P) and 
lysophosphatidylcholine (LPC), nucleotides adenosine triphosphate (ATP) 
and uridine triphosphate (UTP), as well as classical protein chemokines 
CX3CL1 ((fractalkine) and monocyte chemotactic protein (MCP-1 or CCL2) 
(Gude et al., 2008, Lauber et al., 2003, Elliott et al., 2009, Chekeni et al., 
2010, Truman et al., 2008, Kobara et al., 2008). ATP and UTP whose 
release is mediated by pannexin channels seem to serve as a short-range 
find me signal due to their readily degrading by extracellular nucleotidases 
(Hochreiter-Hufford and Ravichandran, 2013, Chekeni et al., 2010). Their 
sensing by macrophage may be through the P2Y2 receptor (Elliott et al., 
2009). CX3CL1 is released from apoptotic B-lymphocytes and attracts 
macrophages via chemokine (CX3-C motif) receptor 1 (CX3CR1). CX3CL1 is 
contained within extracellular vesicles derived from apoptotic B cells and may 
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enhance the attraction effects (Truman et al., 2008). The release of LPC by 
apoptotic cells is dependent on caspase 3 and its recognition appears via the 
phagocyte receptor G2A (Peter et al., 2008). In addition to serving as ‘find 
me’ signals, some of the molecules exhibit other roles during the clearance of 
apoptotic cells. For example, ATP increases binding of apoptotic cells to 
macrophages (Marques-da-Silva et al., 2011). CX3CL1 has been shown to 
cause the expression of a bridging molecule of milk fat globule epidermal 
growth factor (MFG-E8) on macrophages, which lead to the enhanced 
apoptotic cell clearance (Miksa et al., 2007). LPC, S1P and nucleotides also 
shown to attract neutrophils (Chen et al., 2006b, Florey and Haskard, 2009). 
However, apoptotic cells show minimal, if any, neutrophil recruitment 
implying there are ‘keep out’ signals that coordinate with ‘find me’ signals to 
decide the types of recruited phagocytes (Savill et al., 2002, Gregory and 
Pound, 2010).  The first molecule found as the ‘keep out’ signal was 
lactoferrin by its ability to inhibit the migration of granulocytes, but not 
macrophages, as shown both in vitro and in vivo (Bournazou et al., 2009). 
 
When macrophages are recruited to the site of apoptosis, they need to 
distinguish their targeted dying cells from viable cells. This ‘recognition’ is 
achieved by ‘eat me signals’ on apoptotic cells and ‘don’t eat me’ signals 
(CD47 and CD31) on viable cells (Truman et al., 2008, Gregory and Pound, 
2010).  Eat me signals include the translocation of intracellular structures to 
extracellular sites such as DNA, calreticulin and annexin I, glycosylation of 
surface proteins or changes in surface charge, expression of intercellular 
adhesion molecule 3 (ICAM-3) and low-density lipoprotein (LDL)-like moiety, 
binding of serum proteins to the apoptotic cell, including thrombospondin and 
complement C1q (Gregory and Pound, 2010, Schlegel et al., 1999). The 
most important signal may be the exposure of the phospholipid 
phosphatidylserine (PS) on the outer plasma membrane leaflet since its 
recognition by macrophages appears to be crucial in clearance of apoptotic 
cells (Tennant et al., 2013, Grimsley and Ravichandran, 2003). The co-
localization of calreticulin and annexin I with PS on the surface of apoptotic 
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cells enhance the phagocytosis (Arur et al., 2003, Gardai et al., 2005). The 
recognition of apoptotic cells by phagocytes depends on the various 
receptors on the surface of phagocytic cells. For example, PS can be 
recognised directly by PS- recognition receptors including BAI-1 (brain-
specific angiogenesis inhibitor 1), TIM-4 (T cell immunoglobulin mucin 4), 
and Stabilin-2, or indirectly through bridging molecules, for example, Tyro-3, 
Axl, and Mer, which bind PS via Gas6 and protein S, as well as αvβ3/5 
integrins, which bind MFG-E8 (Miyanishi et al., 2007, Park et al., 2007, Park 
et al., 2008b, Hanayama et al., 2002).  Other receptors on the surface of 
macrophage include CD14 that binds ICAM-3, the scavenger receptors, 
which binds LDL (Devitt et al., 1998, Gordon, 1999).  
 
The engulfment and processing of apoptotic cells by macrophages involves 
the activation of guanosine triphosphatases (GTPases) and subsequent 
cytoskeletal organisation of the phagocyte membrane (Gumienny et al., 
2001).  The quick and effective clearance of apoptotic cells by macrophages 
is important since apoptotic cells, in contrast to necrotic cell death, do not 
release their cellular constitutes, which would prevent an immunogenic 
response.  Furthermore, the phagocytosis of apoptotic cells by macrophages 
has been shown to suppress the production of pro-inflammatory cytokines 
such as IL-6, IL-8, IL-12, and TNFα, as well as activating downstream 
signalling pathways that cause the up-regulation and secretion of anti-
inflammatory mediators such as IL-10, TGF-β (Voll et al., 1997, Fadok et al., 
1998, McDonald et al., 1999, Ogden et al., 2005, Gregory et al., 2011).  
 
Genes that control the removal of apoptotic cells may also function in the 
activation of cell death. Blocking the engulfment genes (ced-6 and ced-7) in 
C.elegans enhances cell survival when cells are subjected to pro-angiogenic 
signals (Hoeppner et al., 2001). Mutations in engulf genes in C.elegans 
enhances the survival of cells with partial loss of function of killer genes and 
these mutations alone allow the survival and differentiation of some cells that 
were programmed to die by apoptosis (Reddien et al., 2001).  In vertebrates, 
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the elimination or inhibition of macrophages interrupts apoptosis-related 
functions (Diez-Roux and Lang, 1997, Lang and Bishop, 1993, Little and 
Flores, 1993). The engulfment machinery may contribute to cell killing. 
 
1.3.3 Apoptosis in the tumour microenvironment 
Evasion of cell death is a well-established feature of tumour cells (Hanahan 
and Weinberg, 2011). Mechanisms contributing to evasion of apoptosis and 
carcinogenesis include defects or mutations of the p53 protein, also called 
tumour protein 53 (or TP 53). TP53 is one of the best known tumour 
suppressor proteins and defects in the p53 tumour suppressor gene have 
been associated with more than 50% of human cancers (Shen et al., 2013). 
Promoting cell death by inducing apoptosis has been long represented as an 
important effector mechanism in cancer treatment. However, recent studies 
show that apoptosis can promote tumour growth (Ford et al., 2015). Indeed, 
high rates of apoptosis have been observed in many malignant tumours and 
high level of apoptosis have also been shown to correlate with poorer 
prognosis in some cancers indicating the potential of apoptosis to drive 
oncogenesis (de Jong et al., 2000, Alcaide et al., 2013, Ucker and Levine, 
2018).  
 
It seems likely that apoptotic tumour cells actively modulate the tumour 
microenvironment in favour of contributing to the development of tumours. 
The exact mechanism underlying the pro-oncogenic roles of apoptosis are 
still unclear. Possible mechanisms include apoptotic tumour cells lead to 
compensatory proliferation by releasing growth factors, promote 
angiogenesis by attraction and modulation of macrophages and provide 
antitumor immunity (Gregory et al., 2016, Gregory and Pound, 2010). . 
 
The phenomenon of compensatory proliferation was first observed in 
Drosophila when irradiated discs recovered to form adult structures of normal 
size and shape (Bryant and Fraser, 1988, Haynie and Bryant, 1976). More 
recently, dying tumour cells were shown to stimulate the growth of surviving 
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tumour cells and caspase-3 was involved in the growth stimulation (Huang et 
al., 2011). The interactions of apoptotic cells and macrophages appears to lie 
at the centre of pro-oncogenic events as the fundamental roles of TAMs in 
angiogenesis and anti-inflammatory signalling (reviewed in 1.2.1). Detailed 
studies on the role of apoptosis in the pathogenesis of aggressive starry-sky 
B-cell non-Hodgkin’s lymphoma, prototypically BL have been carried out in 
our group (Ford et al., 2015).  Suppression of apoptosis by expression of the 
anti-apoptotic genes bcl-2 or bcl-xl leads to impaired tumour growth, reduced 
TAM accumulation as well as decreased angiogenesis when lymphoma cells 
were implanted into SCID mice (Ford et al., 2015). In this same model, in situ 
gene expression profiling of TAMs revealed functional clusters closely 
associated with anti-inflammatory, proangiogenic, and extracellular matrix 
deposition and remodelling pathways (Ford et al., 2015). 
 
1.4 Zebrafish models for cancer research  
Zebrafish has emerged as an attractive vertebrate model organism for 
scientific research of human tumours since they provide various advantages 
over traditional vertebrate models, that include rapid generation time (only 3 
to 4 month), large brood size (100 to 200 eggs weekly per adult female), the 
ease of keeping high stocking density in a relatively small space (Lieschke 
and Currie, 2007).  
 
Moreover, zebrafish embryos are transparent during the early stages of life 
(through to 7 days post-fertilization (dpf)) and externally fertilized, which 
offers a unique opportunity for in vivo live imaging. The availability of 
transgenic zebrafish lines with specific fluorescent-tagged cell types of 
interest offers a direct readout of distinct cell populations by fluorescent or 
confocal microscopy. 
 
Zebrafish has functional homologues for about 70% of human disease 
associated genes (Schartl, 2014). Most importantly, there are striking 
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histological similarities between carcinogen-induced neoplasms in zebrafish 
and certain human tumours (Grabher and Look, 2006, Stern and Zon, 2003). 
A high degree of conservation in gene expression between zebrafish and 
human tumours and oncogenes further validate zebrafish as a viable 
predictive organism for modelling human cancers (Yang et al., 2004, Patton 
et al., 2005, Lam et al., 2006, Amatruda et al., 2002). 
 
1.4.1 Hematopoiesis in zebrafish  
The hematopoiesis program is highly conserved during evolution and in the 
past two decades many studies have shown that both transcriptional 
regulation and cellular makeup of the hematopoietic system is largely 
conserved from zebrafish to humans. 
 
Zebrafish also has two waves of hematopoiesis the primitive and the 
definitive hematopoiesis. Unlike mammals and birds, the primitive wave of 
zebrafish occurs in two intra-embryonic locations: the intermediate cell mass 
(ICM) in the trunk ventral to the notochord, and the rostral blood island (RBI) 
originating from the cephalic mesoderm (Detrich et al., 1995, Paik and Zon, 
2010). The primitive wave generates myeloid cells. These primitive blood 
cells start to circulate in the embryo from 24 hours post-fertilization (hpf). 
Definitive hematopoietic stem cells (HSCs) arise from the ventral wall of the 
dorsal aorta and then migrate to the posterior region in the tail called the 
caudal hematopoietic tissue (CHT) (Murayama et al., 2006).  This posterior 
wave mainly gives rise to erythrocytes and some myeloid cells.  
Lymphopoiesis originates in the thymus from 3dpf and by 4dpf, HSCs home 
to the kidney marrow which appears to be analogous to the bone marrow in 
mammals (Paik and Zon, 2010). 
 
The first macrophages are detected in the lateral mesoderm of the head, just 
anterior to the cardiac field at the 3-somite stage and migrate to the yolk sac, 
where macrophages differentiate and either enter the blood circulation or 
invade the head mesenchyme (Lieschke et al., 2002, Herbomel et al., 1999). 
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These primitive macrophages are active from 26 hpf in the ducts of Cuvier 
where macrophages were observed to engulf apoptotic erythroblasts from 
the blood stream (Herbomel et al., 1999). Gradually multiple lineages of 
macrophages derived by definitive hematopoiesis replace primitive 
macrophages and between 24 and 48 hpf, some of the yolk sac 
macrophages, most of which were anchored to or spread on the basal lamina 
of the epidermis, start entering the thin monolayered epithelium (Herbomel et 
al., 2001). Following the second wave of hematopoiesis, macrophage 
precursors extravasate into tissues throughout the whole body and 
differentiate into tissue macrophages (Torraca et al., 2014). To date, there 
are two popular transgenic zebrafish with macrophages labelled using either 
the macrophage-expressed gene 1 (mpeg1) promoter or microfibrillar-
associated protein 4 (mfap4) promoter. However, mpeg1 transcription 
attenuates in the presence of intracellular pathogens at both endogenous 
and transgenic loci while transgenic lines using mfap4 as promoter have 
macrophages that remain stable throughout several days of infection (Benard 
et al., 2015, Walton et al., 2015). 
 
From 4dpf, the zebrafish kidney starts to develop and will progressively 
replace the embryonic hematopoietic system. Although understanding of B 
cell development in zebrafish is relatively limited, a B cell specific transgenic 
line (Tg(IgM1::eGFP) reveals that kidney would seem to be the main organ 
for B cell development and it is also one of the three sites where B cells 
initially appear around 20 days (Page et al., 2013). This model also suggests 
that B-cell ontogeny in zebrafish is similar to human as there are pro-B, pre-
B, and immature/mature B cells in the adult kidney. 
  
Many orthologues of the transcription factors that are involved in mammalian 
hematopoiesis are found in zebrafish, such as stem cell leukemia (SCL), a 
zinc finger transcription factor gata2, an ets domain containing gene etsrp 
(Paik and Zon, 2010). Gene expression analyses show that the temporal and 
spatial expression patterns of zebrafish hematopoietic development are 
comparable to their mammalian counterparts.  
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In summary, the zebrafish immune system shares similar genomic pathways 
and contains all counterparts of human immune cells including macrophages, 
neutrophils, T cells and B cells, thereby providing a relevant model system 
(Meeker and Trede, 2008, Traver et al., 2003).  
 
1.4.2 Xeno-transplantation in the transparent zebrafish embryo 
Xenograft models in zebrafish, especially embryos without a fully developed 
immune system are being exploited to study cancer-related phenomena such 
as invasion, metastasis, angiogenesis, and cancer stem cell renewal in vivo 
and in real time (Amatruda et al., 2002, Nicoli and Presta, 2007, Nicoli et al., 
2009, Nicoli et al., 2007).  
The zebrafish model provides unique advantages for visualization of tumor 
cell behaviour and interaction with host cells. For example, the Tg 
(fli1::eGFP) embryo in which the friend leukemia integration 1 transcription 
factor (fli1) promoter drives the expression of eGFP in all blood and 
lymphatic vessels throughout embryogenesis can be used for analyzing 
tumor-induced lymph/angiogenesis. The Tg(flk1::mCherry) and 
Tg(flk1::eGFP) are also available as  transgenic lines labelling all blood 
vessels (Jin et al., 2005). The transgenic lines that specifically label 
macrophages Tg(mpeg1::eGFP) and Tg(mfap4::Turquoius) can be used to 
study inflammatory responses (Oehlers et al., 2015).  In a zebrafish–
Mycobacterium marinum infection model, with the help of blood vessel-
labelled and macrophage-labelled zebrafish models, Stefan H. Oehlers and 
his colleagues found that mycobacterial growth is intimately associated with 
angiogenesis suggesting the potential utility of host-targeting by anti-
angiogenic agents as adjunct therapies for mycobacterial disease (Oehlers et 
al., 2015).  
Several human cell lines have been transplanted into zebrafish embryos and 
show different capacities for proliferation and migration in zebrafish. For 
example, Wietske van der Ent et.al compared several uveal melanoma cells 
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and indicated that cells derived from metastases showed more migration and 
proliferation than cells derived from the primary tumors in zebrafish (van der 
Ent et al., 2014). 
Xenografts in zebrafish are also robust models for tumour metastasis 
studies. The zebrafish can also serve as a valuable mode to study cancer 
cell homing to the hematopoietic niche and to establish a screening platform 
for the identification of factors and mechanisms contributing to the early 
steps of bone metastasis (Sacco et al., 2016). Co-injection of TAMs and 
cancer cells into zebrafish showed that TAMs (human TAM isolated from 
primary breast, lung, colorectal, and endometrial cancers) and M2-like 
macrophages (induced by IL4, IL10, and TGF-β) rather than M1-like 
macrophages (IFNγ-lipopolysaccharide–induced) enhance metastases by 
binding tumour cells and mediating their intravasation (Wang et al., 2015).  
Still, despite the high conservation of gene function between zebrafish and 
humans, the potential differences in zebrafish tissue niches and/or missing 
microenvironmental cues could limit the relevance and translational utility of 
data obtained from zebrafish human cancer cell xenograft models. 
1.4.3 Transgenic zebrafish models of immune system malignancy 
Following on from early studies of tumour induction with chemical 
carcinogens, within the past decade, advances in genetic techniques have 
led to the generation of new zebrafish cancer models including creation of 
numerous mutant and transgenic lines(Amatruda and Patton, 2008, Meeker 
and Trede, 2008). These models are able to induce tumours that 
phenotypically resemble their human counterparts. 
 
The first transgenic immune system cancer model in zebrafish was T cell 
acute lymphoblastic leukemia (T-ALL) established by over-expression of 
mouse cmyc gene fused with eGFP under control of zebrafish rag2 promoter 
(Langenau et al., 2003). Green leukemic cells were initially detected in the 
thymic region with subsequent local spread into surrounding tissues. Cells 
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later spread into muscle and abdominal organs including the kidney marrow. 
Molecular and cellular characterization of these green cells showed that they 
were clonal and arrested at an early stage of T cell development. Green T 
lymphoblasts also express the zebrafish orthologues of the human 
oncogenes, tal1/scl and lmo2 (Langenau et al., 2005). The onset of T-ALL is 
early in this model and diseased zebrafish normally die before sexual 
maturity. To obtain a stable line of ALL, an inducible transgenic T-ALL model 
was established by inserting the myc gene into a floxed dsred construct. In 
this line, T cells only express MYC when the floxed segment is removed by 
heat-shock-induced expression of the Cre recombinase (Langenau et al., 
2005). 
 
The second T-ALL model was generated by putting the human T-ALL 
oncogene, notch1 under control of the rag2 promoter. This model develops 
T-ALL at a later stage (about 5 months of age) with similar pathology to that 
seen in the myc model. Unlike the myc model, they do not show increased 
expression of tal1/scl and lmo2, and myc-a and myc-b are not expressed 
above normal levels (Chen et al., 2007) 
 
The only B cell malignancy model in zebrafish is a B cell leukemia model 
generated by expression of the fusion TEL-AML1 (ETV6-RUNX1) under the 
control of the ubiquitous promoter, Xenopus elongation factor 1α or zebrafish 
β-actin rather than zebrafish lymphoid-restricted promoter, rag2 promoter 
(Sabaawy et al., 2006).  
 
Modelling B cell malignancy in zebrafish has been challenging. The only B 
cell malignancy model in zebrafish established so far is a B cell leukemia 
model that was generated by expression of the fusion TEL-AML1 (ETV6-
RUNX1) under control of the ubiquitous promoters, Xenopus elongation 
factor 1α or zebrafish β-actin rather than the zebrafish lymphoid-restricted 
rag2 promoter (Detrich et al., 1995).  
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1.5 Outline & Aims of this project 
The over-arching hypothesis of the project is that apoptotic tumour cells 
contribute to the pro-oncogenic microenvironment in aggressive B-cell 
lymphoma. This project aims to test the hypothesis that in aggressive B-cell 
lymphoma, apoptotic tumour cells produce early stimulatory signals for 
tumour lymph/angiogenesis and leukocyte infiltration and activation.  
 
In order to address this hypothesis, the first part of the project aimed to 
generate a transgenic B cell lymphoma model in zebrafish. Since myc has 
been established to be the primary oncogene in BL, the overexpression of 
myc in B cells was used as the strategy to induce B cell lymphoma.  
 
The second part of the project aimed to establish a xenograft zebrafish 
embryo model to study the pro-oncogenic mechanisms of apoptosis. Apo-
EVs and TAMs were chosen as the candidates and their trophic effects in 
zebrafish were investigated.    
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Chapter 2 Materials and Methods   
2.1 Tissue culture techniques 
2.1.1 Cell culture 
BL cells 
The EBV-negative BL line, BL2 was chosen for initial xenotransplantation   
studies, together with an apoptosis-resistant bcl2 transfectant (BL2-bcl2). 
The BL2-bcl2 line used in the present study was a stable bcl-2 transfectant 
established by bcl2 expression vector pCΔJ bcl2 (Milner et al., 1992, 
Tsujimoto et al., 1987). Cells were cultured in RPMI 1640 medium containing 
10% batch selected fetal bovine serum (FBS), L-glutamine (2 mM), 100 U/ml 
penicillin and 100µg/ml streptomycin. All cells were kept in a humidified 
condition of 37oC or 34oC and 5% CO2, in 25 cm2 or 75 cm2 tissue culture 
flasks. In order to keep cells in logarithmic growth phase, all cell lines were 
maintained by replacing fresh culture medium every two or three days. 
Melanoma cells 
A375, a human malignant melanoma cell line, was used in this project as a 
comparison to BL2 cell in zebrafish transplantation experiments. This cell line 
was a gift from Dr Liz Patton (the University of Edinburgh). Cells were 
cultured in DMEM media containing 10% batch selected fetal bovine serum 
(FBS), L-glutamine (2mM), 100 U/ml penicillin, 100 µg/ml streptomycin, 
10mm Sodium Pyruvate Solution and 1%MEM NEAA (100X). All cells were 
kept in a humidified condition of 37oC or 34oC and 5% CO2, in 25 cm2 or 75 
cm2 tissue culture flasks.  
 
2.1.2 Adaptation of BL cells to grow at low temperatures 
The optimum temperature for zebrafish growth and development is 28.5°C， 
but this will not support growth of mammalian cells. Therefore, to establish a 
xenograft model an intermediate temperature was sought which was capable 
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of sustaining BL2 cells at high viability and allowing them to proliferate while 
also allowing zebrafish to develop normally.   
  
BL2 cells were cultured at 35oC and maintained for 2 weeks and then 
transferred to 34oC. Zebrafish were kept at 28.5°C until 2.5 days post 
fertilisation (dpf) and was moved to 34oC after being injected with BL cells 
and kept at 34oC. 
 
2.1.3 Generation of BL cell lines & melanoma cell line that are fluorescently 
tagged 
The modification of mammalian cells for the expression of genes encoding 
fluorescent protein was carried out using two strategies.  
2.1.3.1 Transfection of cells with desired plasmid construct 
The pcDNA3.1(+) (Invitrogen) with strong promoter CMV was chosen as the 
expression vector. pAmCyan (Clontech) was used as the fluorescent gene 
provider. Briefly speaking, the pAmCyan gene was inserted to the 
pcDNA3.1(+) backbone.  
DNA digestion and purification 
To get the backbone of pcDNA3.1(+) and insert of pAmCyan, both plasmids 
were double digested by Hind III and EcoR I. Single digestions by either Hind 
III or EcoR I were also performed (table 2.1, 2.2). After digestion at 37oC 
overnight, digestion samples of pcDNA3.1(+) was run on 0.8% agarose gel 
for up to 4 hours at 120 V; digestion samples of pAmCyan was run was run 
on 0.8% agarose gel for 1 hour at 120 V. The target band was excised from 
the gel under UV light (254-366 nm) using a clean disposable scalpel. For 
purification of DNA from agarose gel, Qiangen Gel Extraction was employed 
following manufacture instructions. DNA was quantified by nanodrop and by 








Name Hind III (µl) EcoR I (µl) Double (µl) 
pcDNA3.1(+) 0.25 0.25 0.25 
Hind III 0.125 0 0.125 
EcoR I 0 0.125 0.125 
10X NEB2 1 1 1 
dH2O 8.625 8.625 8.5 
Total 10 10 10 
Table 2.1 pcDNA3.1(+) digestion 
 
Name Hind III(µl) EcoR I (µl) Double (µl) 
pAmCyan 0.25 0.25 0.25 
Hind III 0.125 0 0.125 
EcoR I 0 0.125 0.125 
10X NEB2 1 1 1 
dH2O 8.625 8.625 8.5 
Total 10 10 10 
Table 2.2 pAmCyan digestion 
DNA ligation 
Ligation of pcDNA3.1(+) backbone and pAmCyan insert was achieved by 
using T4 ligase and was performed in T4 ligation buffer. 1µgof back bone 
and appropriate amount of insert (calculated by the formula below) at the 
molar ratio of 5:1 for insert to backbone were ligated overnight at 16-21°C. 
Two ligation reactions comprising one containing no ligase and the other 
containing no insert DNA were used as control. 
 
ng of backbone X kb of insert





Transformation using electroporation 
The pcDNA3.1(+)-pAmCyan was prepared as described above and plasmid 
was dissolved in TE which was provided in Qiangen Gel Extraction kit. 
Because Tris can kill cells after electroporation, buffer was replaced by 
water. Specifically, 1/10 volume 3M NaOAc (pH5.2) was add to 10 µg DNA.  
After mixing, 2X volume EtOH was added and mixed following lacing on dry 
ice for 10 minutes.  DNA was spun at 14,000g for 10 minutes and 
supernatant was removed. Pellet was washed by 70% EtOH and dissolved in 
10 µl of sterile water. 
 
106 cells growing at logarithmic phase were suspend in100 µl nucleofector 
solution (prepared following manufacture guideline) and mixed with 2 µl 
plasmid (1 µg/µl). Mixed sample was transferred into amaxa cuvette and put 
on the nucleofector device. Electroporation was performed using program R-
009. Immediately 500µl of pre-warmed culture medium was added into the 
cuvette and then cells were transferred into a 12-well plate. 
2.1.3.2 Transfection of cells with lentivirus 
Cells growing at logarithmic phase were diluted into culture medium to a final 
concentration of 105 cells/ml. 2 ml of cells were transferred into 15 ml FACON 
tubes and different volumes of virus were added to the cells such that the 
final multiplicity of infection (MOI) equals 0,0.1,0.5,1,5,10,25,50 per tube. 
Volume of virus was calculated by the formula shown as below. Final 
concentration of 1µg/ml polybrene was added to enhance transfect 
efficiency. Cells were spun at 800 xg for 90 minutes at 32oC. Each cell pellet 








2.1.4 Selection of successful transformations  
Antibiotic knock down 
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Cells were checked for target fluorescent protein expression 2 days after 
transformation.  Cells were centrifuged at 200 xg for 5 minutes and 
suspended in culture medium with Blasticidin (Invitrogen). The amounts of 
Blasticidin for different cells were determined by kill curve. Cell medium was 
removed and replaced by fresh culture medium with Blasticidin every two 
days until antibiotic-resistant colonies could be identified (10-12 days after 
selection). Cells were then moved to incubator at 37°C, for 7-10 days. 
 
2.1.4 Growth kinetics assay 
Cells were resuspended at 2x105 viable cells/ml in culture media and plated 
on 24-well plates (Nunc). Cells were incubated at 37˚C, 5% CO2. The viability 




2.1.5 Induction of apoptosis of BL cells 
2.1.5.1 Apoptosis induction by UV radiation 
UV induced apoptosis of BL cell lines has been well characterised previously 
by the Gregory laboratory and reliable methods established. BL2 cells from 
confluent cultures were transferred into 15 ml Falcon tubes and centrifuged 
(300 xg/5min). After washing in PBS three times (300 xg/5 min) and taken off 
supernatant cells were resuspended at 1x106 cells/ml serum-free RPMI 1640 
medium supplemented with L-glutamine and penicillin/streptomycin and then 
exposed in 100 mJ/cm2 UV-B. The intensity of the UV exposure was 
measured by a UV meter. The time of exposure was calculated using the 
formula:  time required (seconds) = !"",!!! !!
!"#"$ !"#$%&'
 
When using CL-1000 Ultraviolet Crossslinker, 300 mJ/cm2 UV-B was used. 
To induce high levels of apoptosis cells were returned to humidified incubator 
of 5% CO2 at 37oC for approximately 3 hours before use. 
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2.1.5. 2 Apoptosis induction by staurosporine 
The broad spectrum protein kinase inhibitor, staurosporine was used as an 
alternative inducer of apoptosis which does not act via damage of DNA. BL2 
cells from cultures were transferred into 15 ml Falcon tubes and centrifuged 
(300 xg/5 minutes). After washing in PBS three times (300 xg/5 min) and 
taken off supernatant cells were resuspended at 1x106 cells/ml serum-free 
RPMI 1640 medium supplemented with L-glutamine and 
penicillin/streptomycin and staurosporine was added to a final concentration 
of 1 µΜ. To induce high levels of apoptosis cells were returned to humidified 
incubator of 5%CO2 at 37oC for approximately 3 hours before use. 
 
2.1.6 Assessment of apoptosis of BL cells by flow cytometry 
BL2 cell lines  
Approximately 5x105 cells were centrifuged (300 xg/5 min) and washed with 
3 ml of cold AxV binding buffer (14 mM sodium chloride, 10 mM HEPES and 
2.5 mM calcium chloride, pH 7.4) then resuspended in 100 µl AxV binding 
buffer.  1 µl of AxV-Alexa 488 was added and cells were incubated in a 
refrigerator for 15 minutes.  After addition of 400 µl of cold AxV binding buffer, 
10µl of PI was added and cells immediately analysed by flow cytometry. 
BL2 fluorescent-tag lines  
Approximately 5x105 cells were centrifuged (300xg/5 minutes) and washed 
with 3 ml of cold AxV binding buffer (14 mM sodium chloride, 10 mM HEPES 
and 2.5 mM calcium chloride, pH 7.4) then resuspended in 100 µl AxV 
binding buffer.  1 µl of AxV-R-phycoerythrin conjugate was added and cells 
were incubated in a refrigerator for 15 minutes. After addition of 400 µl of 
cold AxV binding buffer, 5 µl of SYTOX BLUE was added and incubated for 
5minutes before cells were analysed by flow cytometry. 
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2.1.7 Assessment of proliferation of BL cells by Immunohistochemistry (IHC) 
2.1.7.1pHistone3 staining 
105 cells were washed in DPBS once and resuspended in 100 µl of 10% 
BSA/DPBS. 105 Cells in 100 µl were added onto each slide in the cytospin 
chamber and cytocentrifugated for 3 minutes at 300g. After drying the slide 
for 2 hours at room temperature, slides were fixed in ice-cold acetone at 4°C 
for 10 minutes.  Slides were washed twice in DPBS and loaded into 
Sequenza chambers. Cells were blocked by 125 µl of 1x casein protein for 
10 minutes and then 125µl primary antibody (diluted in 1x casein protein 
block) (table 2.3) was added into each slide or no primary antibody for control 
slide without washing protein block off. After drying, the slides were washed 
twice by DPBS and 125 µl secondary antibody (diluted in 1x casein protein 
block) was added into each slide for 30 minutes. Slides were washed twice in 
DPBS following once in water. Slides were mounted using histomount and 





PHH3 (anti-rabbit) 1/1000 Abcam 
Alexa Fluor® 546 1/250 invitrogen 
Table 2.3 Antibodies used for IHC of cells in vitro 
 
2.1.8 Preparation of extracellular vesicles from UV-treated cells 
2.1.8.1 3-Step Differential Centrifugation Method 
BL2 and/or BL2-Bcl-2 cells were washed once by RPMI 1640 and resuspend 
at 4 x 106 cells/ml in 0.1 µm-filtered RPMI 1640 medium containing 0.1% 
BSA, L-glutamine (2mM), 100 U/ml penicillin and 100µg/ml streptomycin. 
Cells were exposed to 100 mJ/cm2 UVB then incubate at 370C for 2 hours. 
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Cells were then cleared by centrifuging twice at 400 xg for 5 minutes at 20°C 
followed by filtration of supernatant through a pre-wet 5 µm filter. EVs were 
then isolated from cleared supernatant by centrifugation at 2,000 xg for 30 
minutes at 4°C. EVs form a pellet that could be resuspended in an 
appropriate 0.1 µm-filtered media/buffer. 
 
2.1.8.2 Optimised gentle filtration method 
BL2 and/or BL2-Bcl-2 cells were cultured at 20 x 106/ml in 50% X-vivo 20 and 
induced into apoptosis by UV treatment. The cells were usually split 1/2 the 
day before isolation. These culture conditions induce a fairly synchronous 
induction of apoptosis which is monitored by annexin V staining. Samples 
were taken at 1 hour, 3 hour and/or 5 hour and the EVs isolated by gentle 
centrifugation and two filtration steps – a 5 µm mesh filter and a 1.2 µm 
syringe filter. Specifically, cells were resuspended by swirling the flasks and 
decanted into 50ml Falcon tubes and spun at 300 xg for 5minutes, 20oC and 
then supernatant discarded. Cells were re-suspended in a small volume of 
0.1 µm filtered 50% x-vivo 20 and counted on the Attune by using events/µl 
on viable cell gate to calculate cell concentration with the aim of adjusting 
concentration to 20 x 106/ml with 0.1 µm filtered 50% x-vivo 20. Cells were 
UV treated for a total of 300mJ/cm2 as 6 x 50 mJ/cm2. Cells were monitored 
by AxV/Sytox blue on the Attune at hourly intervals swirling the flask to 
completely re-suspend the cells at each time point. At the appropriate time 
point, cells were spun at 25 xg for 1h at 4°C by adding 1.5 volume DPBS and 
then the supernatant were filtered through 5µm Pluristrainer mesh filter onto 
a 50 ml Falcon following a 1.2 µm syringe filter. 
 
2.1.9 Preparation of Macrophages from human blood 
Blood was prepared using the method kindly provided by Ian Dransfield and 
John Marwick of Lung Inflammation Group. Freshly drawn venous blood was 
collected in a 50 mL syringe. 40 mL blood was added into a 50 mL BD 
Falcon tube containing 4 mL of 3.8% sodium citrate solution. The tube was 
capped, inverted to mix and sealed with parafilm. Blood was centrifuged at 
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350 xg for 20 minutes at room temperature to separate cells from plasma. 
The top layer of platelet rich plasma (PRP) was transferred into 50 mL tubes 
without disturbing the pelleted cells and aliquoted as 10 ml per glass vials 
with addition of 220 µl 1M CaCl2 to generate autologous recalcified plasma 
(serum) by gently mixing and incubating for 1 hour at 37°C. Leukocytes were 
enriched from the pelleted cells by differential sedimentation of erythrocytes 
by dextran. Specifically, the bottom layer was resuspended in 6 mL of 
dextran and topped up to 50 mL with 0.9% sodium chloride. The mixture was 
allowed to stand undisturbed for a maximum of 20 minutes or until 
sedimentation had taken place. The top layer was then moved into another 
50 ml BD Falcon tube and topped up to 50 ml with 0.9% sodium chloride and 
spun at 350 xg for 6 minutes.  After removing the supernatant the leukocytes 
were resuspended in percoll gradients of 81%, 70% and 55%. The gradient 
was spun at 720 xg for 20 minutes and mononuclear cells (MNCs - 
lymphocytes and monocytes) were collected from the 55%/70% interface and 
washed by topping up to 50 mL with 0.9% Sodium Chloride (Baxter) and 
spinning at 230 xg for 6 minutes. MNCs were counted before resuspending 
in the required volume of MACS buffer (PBS (pH 7.2) containing 0.5% BSA 
(or autologous serum) and 2 mM EDTA, sterile filtered through 0.22 µm 
filter). Monocytes were isolated from MNCs using Pan monocyte isolation kit, 
human (MACS Miltenyi #130-096-537) following manufacturer’s instruction. 
The isolated monocytes were cultured in IMDM (Life Technologies) plus 1X 
Pen/Strep and 2 mM L-Glut (IMDM/PS/LG) for 40 – 60 minutes at 37°C to 
adhere onto tissue culture plastic and then the culture media was replaced 
by IMDM/PS/LG containing 2% Human AB serum. Monocytes were 
incubated for 5-7 days in total at 37°C, 5% CO2 before use in downstream 
assays. 
2.2 Zebafish methodology 
2.2.1 Fish husbandry and housing 
Zebrafish were kept and raised in the fish facility based in Queen’s Medical 
Research Institute with a 14 hour-light and 10 hour-dark cycle at 28.5oC 
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under the standard protocol of Westerfield(Westerfield, 1995b). The females 
have larger silver stripes and bigger white belly. Males are slimmer and have 
gold stripes between the blue stripes. Embryos were obtained by crossing 
sex mature fish in a pair-wise manner. Embryos were raised in conditioned 
aquarium water containing 0.00001% methylene blue or E3 media. Some 
embryos were kept with 0.003% 1-phenyl-2-thiourea (PTU) from 20 hours 
post fertilisation (hpf) to avoid pigmentation. All embryos were staged by hour 
post fertilization (hpf) or day post fertilization (dpf) using standard procedures 
(Kimmel et al., 1995).  
In this study the reporter lines Tg(fli1::eGFP)(Lawson and Weinstein, 2002), 
Tg(flk1::mCherry), Tg(mpeg1::mCherry) (Ellett et al., 2011) and 
Tg(mpeg1::mCherry/tnfα::eGFP) (Nguyen-Chi et al., 2015) were used to 
monitor tumour cells and macrophage behaviour as well as tumour-induced 
angiogenesis.  
2.2.2 Microinjection  
Injection needles were pulled from glass capillary using P-97 Flaming/Brown 
micropipette Puller. All injections were performed under stereomicroscope 
microscope with the help of gas-pressure instrument PV 820 Pneumatic 
Picopump to provide consistent injections. 
2.2.2.1 Transplantation of cells 
Cells in the Log Phase were washed and resuspended in 1:1 of 
matrigel:DPBS or 0.5% Polyvinylpyrrolidone (PVP40) in DPBS at desired 
concentration. Cells were loaded into injection needle that was placed in the 
micromanipulator. Zebrafish embryos were kept at 28.5oC until 2 dpf for 
injection. A final cell number of 200-500 cells/fish for injection was achieved 
by adjusting the size of cut end of the needle (not big enough to cause 
severe physically damage), injection pressure (20-30 psi) and injection time 
(200-300 msec). Injected volume was checked in mineral oil before 
transplantation. Cells were injected into the desired site (yolk sac, brain, 
circulation, pericardial cavity or perivitelline space) of anesthetized zebrafish 
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lying on the agarose coated plate. The transplanted fish were kept at 34oC 
and selected for correct transplantation 2 hours later except the injection into 
circulation was checked immediately after injection. 
2.2.2.2 Microinjection of tol2 transposon system  
A total of 5-10 pg of plasmid DNA and 25-50 pg of synthesized mRNA was 
injected into one cell stage of zebrafish embryo (Kawakami, 2007). 
 
2.2.3 Strategy of generating transgenic zebrafish 
2.2.3.1 Generation of plasmid with a Tol2 constructs 
Most plasmids generated in this project as shown in table 2.4 were using the 
gateway technology unless stated otherwise. p5E-IgM1 was generated from 
the plasmid of IgM1-eGFP (Page et al., 2013) which was a gift from Dr. Brad 
G. Magor (University of Alberta). Others were either obtained from members 
in our group or generated from existing plasmids by myself using gateway 
technology. Plasmids generated through PCR were sequenced by Eurofins 
genomics. 
2.2.3.2 Generation of transgenic zebrafish lines  
Synthetic Tol2 transposase mRNA was co-injected with transgenic 
constructs containing Tol2 elements into one-cell stage embryo. Surviving 
embryos with selection marker were kept until sexual maturity. The founder 
fish were mated with wild type to get F1 generation. The F1 progeny with 
successful integration of transgene into genome were checked by fluorescent 
microscope for presence of selection marker (green heart or blue eye). 
 
2.2.4 FACS sorting, single-cell suspensions of adult/larvae zebrafish kidney 
2.2.4.1 Prepare of single cell suspension  
Kidney was collected by opening the abdomen of zebrafish as shown in 
figure 2.1 (a) and removal of all internal organs to expose the kidney as in 
figure 2.1 (b) using forceps and a dissection microscope. Whole kidney 
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comprising the head, trunk and tail (figure 2.1 (c) (d)) was carefully removed 
away from the body wall by forceps and put into ice-cold staining medium 
(0.9X Dulbecco’s PBS + 5% FCS). Kidney was aspirated vigorously by 1 ml 
pipetteman before filtered through 40 µm Cell Strainer (Falcon) and washed 
by staining media. The flow through was centrifuged and filtered again 
through 40 µm Cell Strainer. 1:1000 Sytox Blue (excited by the 405 nm laser) 
was added for dead cell discrimination.  
 
 
Figure 2.1 Kidney collection of zebrafish juvenile and adult 
(a) Red lines show the dissection for the exposure of abdomen of zebrafish 
(b) Kidney are exposed after removal of organs in the abdomen (c) Cartoon 




2.2.5 IHC on whole-mount embryos 
Zebrafish embryos were fixed in 4% Paraformaldehyde (PFA)/PBS with 0.4% 
Triton X-100 for 2 hours at room temperature (RT) or overnight at 4oC. 
Embryos were washed in DPBT (0.1% Triton X-100 in DPBS) for 5 minutes 4 
times before blocking for 2 hours at RT in 5% goat serum/DPBT. Embryos 
were incubated in 5% goat serum/DPBT containing the primary antibody 
(table 2.4) with gentle shaking at 4 oC over night. Embryos were rinsed with 
DPBT twice and washed in DPBT (0.1% Triton X-100 in DPBS) for 30 
minutes 10 times. Embryos were incubated in 2% goat serum/DPBT 
containing the secondary antibodies conjugated with fluorescent label (table 
2.4) at 4˚C over night and kept in dark as much as possible from this stage.  
Embryos were stained with counting reagent if needed for 30 minutes at RT 
then rinsed twice following washes in DPBT for 20 minutes 10 times. 






PHH3 (rabbit) 1/500 Abcam 
Alexa Fluor® 546 1/250 invitrogen 
Table 2.4 Antibodies used for IHC on whole amount zebrafish embryo 
 
2.3 General molecular biology techniques 
2.3.1 Polymerase chain reaction (PCR) 
PCR reactions were carried out using Q5® High-Fidelity DNA Polymerase 
(New England Biolabs) or CloneAmp™ HiFi PCR Premix (Clontech). 
Appropriate annealing temperatures were selected depending on the length 
of the products and the Tm of the primers (table 2.5). 
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Primer name Sequence 
p5E-IgM1 F Ggggacaactttgtatagaaaagttgcagccctttctagagctcgtgcctcg 







Table 2.5 Primers used for generating plasmids 
 
2.3.2 Restriction enzyme digestion  
Appropriate NEB enzymes and buffers were used for restriction digestions 
following the manufacturer’s instructions. The products of the digestion were 
analysed by agarose gel electrophoresis.  
 
2.3.3 Gel electrophoresis and extraction 
DNA fragments were analysed in 1% Agarose gel with the help of GelRed 
Nucleic Acid Gel Stain (1/10,000) to visualise the DNA under ultraviolet (UV) 
light. Gel extraction was performed using QIAquick Gel Extraction Kit 
(QIAGEN) following the manufacturer’s instructions. 
 
2.3.4 Electroporation of Electrocompetent E.coli and DNA plasmid 
preparation 
1 µl to 5 µl of DNA were transformed into 50 µl One Shot® TOP10 cells using 
electroporator under the setting of 1.7 Kv, 200 Ohms and 25 µF. Immediately 
after electroporation, cells were resuspended in prewarmed (37oC) LB media 
and recovered for 1 hour at 37oC/250RPM. 50 µl of different dilutions of cell 
culture including neat, 1/10 and 1/100 dilutions were plated onto 9 cm Agar 
plates containing TYE Agar with 1% Glucose and appropriate antibiotics. 
After 24 hours incubation at 37oC, several colonies for each plasmid were 
picked and grew in 5 ml volume of LB media containing 1% Glucose 
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appropriate antibiotics overnight at 37oC/250RPM. Qiagen Miniprep Kit （
Qiagen） was used for isolated plasmid DNA as manufacturer’s instructions.  
To get more DNA, cells were transferred to 50ml media containing 1% 
Glucose appropriate antibiotics to grow overnight at 37oC/250RPM. For 
collecting DNA cloning in competent cells, plasmids were prepared using  
Qiagen Midi Prep kit (Qiagen) as per manufactures instructions. 
Concentration (ng/µl) and purity of purified DNA samples were analysed by 
NanoDrop 1000 Spectrophotometer. 
2.4 Image acquisition and Image procession  
All 3.5x and 11x fluorescence images were collected using Leica Stereo AF 
6000 combined with digital camera DFC or Leica M205 FA with Leica 
DFC345 FX and Leica M165 FC with HAMAMATSU digital camera. Higher 
magnification images were taken by Leica TCS SP5 confocal microscope 
(Leica). Confocal stacks were processed for maximum intensity projections 
by Leica software. Images were adjusted for brightness and contrast with 
Adobe Photoshop CS6 if necessary. Overlays of images were generated with 
Adobe Photoshop CS6. Imaris 8.0.2 (Bitplane, Zurich, Switzerland) was used 
to analyse the morphology of macrophages.  
2.5 Statistical analysis 
Values from groups shown as means±SEM using GraphPad Prism software 
(version 6; GraphPad Software Inc., San Diego, CA, USA). Mann whitney 
test was used to detect significant difference between means of two groups, 
and one way Analysis of Variance (ANOVA) was used for analysing 
significant difference among three groups. All significant values are given 




2. 6 List of Regent 






ApopTag® Red In Situ Apoptosis 
Detection Kit 
Millipore 
AxV-Fluos  Roche 
Biomax 300KDa Ultrafiltration Discs Millipore 
Bovine Serum Albumin (BSA) Sigma 
Bradford’s assay solution Bio-Rad 
casein protein block  Vector labs 




Click-iT EdU Alexa Fluor 647 Imaging 
Kit 
Life Technologies 
Dulbecco's Modified Eagle Medium 
(DMEM) 
Gibco 






Fetal bovine serum (FBS) BioWhittaker 
GelRed Nucleic Acid Gel Stain, 
10,000X in water 
Biotium 
Hechest 33342 Sigma 
Hign Fidelity PCR Eco Dry Premix Clontech 
Hybond-P (nitrocellulose) membrane GE Healthcare 




Hydrogen peroxide Sigma 
Hyperfilm ECL GE Healthcare 
Kanamycin  Sigma 
L-glutamine PAA 
Matrigel (Cultrex® Basement 
Membrane Extract,Reduced Growth 
Factor ) 
Trevigen 
Methanol Fisher Scientific 
Minimum Essential Medium Non-
Essential Amino Acids Solution (MEM 
NEAA)(100X)  
Gibco 
Non-fat milk powder Tesco 
Nuclease-Free Water Invitrogen Life 
Technologies 
NuPAGE LDS sample buffer Invitrogen 
NuPAGE MES SDS Running buffer 
20x 
Invitrogen 
NuPAGE Novex 4-12% Bis- Tris pre-
cast gels 
Invitrogen 
NuPAGE reducing agent Invitrogen 
NuPAGE Transfer buffer Invitrogen 
Paraformaldehyde Sigma 
Penicillin Invitrogen 
Propidium Iodide (PI) Bender 
MedSystems 
Protease inhibitor cocktail P8340 Sigma 
PTU (1-phenyl-2-thiourea) Sigma 
Q5® High-Fidelity DNA Polymerase New England 
Biolabs 
QIAquick Gel Extraction Kit QIAGEN 
RPMI 1640 growth medium Gibco 
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SeeBlue Plus2 Pre-Stained Standard Invitrogen 
SIGMAFAST BCIP/NBT Sigma 
Sodium chloride Fisher Scientific 
Sodium Pyrurate Solution Sigma 
SP-DiOC18(3) Invitrogen 
Staurosporine Calbiochem 
Streptomycin Invitrogen Life 
Technologies 
SYTOX® Blue Dead Cell Stain  Thermo Fisher  
Triton X-1000 Sigma 
Trypan Blue Sigma 
Tween20 Sigma 
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2.7 List of Equipment 
Equipment Suppliers 
96-well Nunc-Immuno plate  Thermo 
Class II microbiological safety 
cabinets 
BIOMAT 
Coulter EPICS XL-MCL flow 
cytometer 
Beckman Coulter 
D-78532 Tuttingen Sartorius 
Filter system 0.22µm, 500ml Corning 
Incubators LEEC 
Microplate autoreader Anthos HTII 
Anthos Labtech 
Instruments 
Sigma 1-15K Sigma 
Tissue culture flasks Iwaki 
Tissue culture plates Costar 
 CL-1000 Ultraviolet Crossslinker Ultra-Violet Products 
Zeiss Axiovert 25 Zeiss 
Nucleofector Lonza 
 PV 820 Pneumatic Picopump 
World Precision 
Instruments 
Digital camera C1144O HAMAMATSU 
Leica M165 FC Leica 
Leica M205 FA  Leica 




2.8 List of zebrafish line  
Name Description 
AB wildtype line 
WIK wildtype line 
fli1::eGFP  promoter of fli1a gene drives expression 
of enhanced GFP in the blood 
vasculature, the dorsal aorta, the 
posterior cardinal vein and the thoracic 
duct and lymphatic vessles (Lawson and 
Weinstein, 2002)  
flk1::eGFP promoter of flk1/vegfr2 gene drives 
expression of enhanced GFP in all 
endothelial cells (Jin et al., 2005)  
flk1:: mCherry promoter of flk1/vegfr2 gene drives 
expression of mCherry in all endothelial 
cells (Wang et al., 2010) 
  
mpeg1::mCherry mpeg1-driven transgenes express in 




mCherry labelled macrophages and cells 
will turn green when TNFα signals are 
activated (Nguyen-Chi et al., 2015)  




details in result chapter 3 




Chapter 3 B cell lymphoma transgenic models 
generation and characterization in zebrafish  
3.1 Introduction 
The common characteristic of virtually all BL is chromosomal translocation of 
the myc proto-oncogene to an immunoglobulin (Ig) locus leading to 
deregulation and constitutive expression of c-myc with an overall effect of 
uncontrolled proliferation as well as a reduced threshold for induction of 
apoptosis (God and Haque, 2010, Gregory and Hann, 2000). 
 
Myc is estimated to play a role in 20% of all cancers and to target 15% of all 
known genes (God and Haque, 2010). Myc contributes to the metabolic 
reprogramming that essential for cancer cells to adapt to the tumour 
microenvironment, and highly dependent on cell-intrinsic signals thereof 
(Stefan and Bister, 2017, Crunkhorn, 2017, Camarda et al., 2017).  By 
placing the myc gene under the enhancer region of immunoglobulin (Ig) H 
chain or kappa (Ig kappa) or lambda (Ig lambda) L chain genes in mouse, 
different types of B cell lymphoma including those mimicking BL were 
developed and the phenotypes of lymphoma seemed to be linked to the 
onset time of tumour development (Kovalchuk et al., 2000, Adams et al., 
1985). Despite the opportunities of studying pathogenesis provided by these 
transgenic murine models, it is still difficult to explore early events and 
observe the direct interactions of tumour cells and stromal cells in vivo during 
tumour development and these are possibly achieved by establishing a 
transgenic zebrafish B cell lymphoma model. 
 
The zebrafish immune system contains most if not all counterparts of human 
immune cells including macrophages, neutrophils, T cells and B cells, 
thereby providing a relevant model system. There are several transgenic 
zebrafish lines of immune system malignancies showing morphological and 
genetic similarity to human cancers. T cell acute lymphoblastic leukemia (T-
ALL) models were established by either introducing the mouse cmyc or the 
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human T-ALL oncogene, notch1, into zebrafish under control of the rag2 
promoter (Langenau et al., 2004, Le et al., 2007, Langenau et al., 2003, 
Langenau et al., 2005). The only B cell malignancy thus far reported in 
zebrafish is a leukaemia model induced by over expression of TEL-AML1 
(ETV6-RUNX1) under control of ubiquitous promoters, Xenopus elongation 
factor 1α or zebrafish β-actin (Sabaawy et al., 2006).  However, no zebrafish 




Zebrafish will develop different types of B cell malignancies including 
leukaemia and lymphoma that mimic human cancers by over-expressing 
cmyc in B cells at different stages of B cell development. 
My specific aims: 
1. Generation and analysis of constitutive B cell-specific expression of 
cmyc-eGFP in driving B lymphocyte tumorigenesis in zebrafish. 
2. Generation and analysis of inducible Cre/loxP recombination to 






3.21 Generation of constitutive and inducible B cell-specific expression of 
oncogenic cmyc in driving B lymphocyte tumorigenesis in transgenic 
zebrafish.  
In order to generate a B cell lymphoma model in transgenic zebrafish, it was 
essential to express a relevant oncogene under the control of an appropriate 
B cell promoter. I generated a plasmid construct harbouring mouse cmyc 
fused with enhanced green fluorescent protein (eGFP) under control of the B 
cell specific promoter, the major immunoglobulin M (IgM1) (Page et al., 2013) 
(figure 3.1 a).  
 
This construct of IgM1:cmyc-eGFP, also contained Tol2 transposon 
sequences and was co-injected with Tol2 transposase mRNA into one-cell 
stage embryos (Suster et al., 2009).  The earliest IgM1 B cells appear 
between the dorsal aorta and posterior cardinal vein and also in the kidney 
around 20 days postfertilization (Page et al., 2013) and therefore green heart 
was used as the selection marker to screen embryos. Zebrafish embryos 
with fluorescent green lenses, resulting from crossing individual genetically 
mosaic F0 transgenics to wild-type (WT) fish and indicating the successful 
germline transmission of the transgene to the subsequent F1 generation 




Figure 3.1 Schematic illustration of the strategy of generating 
spontaneous transgenic B cell lymphoma models in zebrafish 
(a) Schematic depiction of the transgene utilized in the spontaneous model. 
(b) Representative image of generated F1 Tg(IgM1::cmyc-eGFP) transgenic 
fish with green heart as selection marker. 
 
In order to image the early events by controlling cell transformation in a 
temporal manner, I generated an inducible Cre/loxP system to control B cell 
specific cmyc expression in transgenic zebrafish.  
 
This transgenic system is comprised of two separate lines as depicted in 
Figure 3.2. The B cell driver line, Tg(IgM1::Cre-ERT2), expressing the Cre-
ERT2 in  B cells under the IgM1 promoter. This line contained green heart as 
selection marker. The second effector line, Tg(IgM1::LoxP-H2B-mCherry-
LoxP-cmyc-eGFP), contained a selection marker of blue lens. This transgene 
was also used as a B cell reporter in this project. Crossing the B cell-driver 




Figure 3.2 Schematic illustration of the strategy of generating inducible 
transgenic B-cell lymphoma models in zebrafish 
Schematic depiction of the system design of Cre-LoxP regulated conditional 
model with representative images of generated transgenic fish. 
 
3.2.2 Analysis of constitutive and inducible B cell-specific expression of 
oncogenic cmyc in driving B lymphocyte tumorigenesis in transgenic 
zebrafish  
Tg(IgM1::LoxP-H2B-mCherry-LoxP-cmyc-eGFP) was not only the effector 
line of inducible model but also could be used as the B cell reporter line in 
this project. Tg(IgM1::LoxP-H2B-mCherry-LoxP-cmyc-eGFP) had B cells 
expressing mCherry signal. 
 
Zebrafish head kidney, which is equivalent to the haematopoietic bone 
marrow of mammals and was chosen as the organ to observe B cells (Page 
et al., 2013, Ivanovski et al., 2009). But the position and structure of 
zebrafish kidney as a single, flattened organ that is adherent to the dorsal 
body wall via connective tissues made it difficult to directly observe mCherry 
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signal from intact adult zebrafish by fluorescent microscopy (Gerlach et al., 
2011).  Therefore, kidney was isolated from adult Tg(IgM1::LoxP-H2B-
mCherry-LoxP-cmyc-eGFP) and cell suspensions from isolated kidney were 
analysed by FACS. The data showed the mCherry+ cells were found in the 
gating for lymphocytes and the percentage of lymphoid cells was similar to 
that of WT zebrafish (figure 3.3). 
 
 
Figure 3.3 FACS analysis of Tg(IgM1::LoxP-H2B-mCherry-LoxP-cmyc-
eGFP) 
(a) The forward scatter (FSC) versus side scatter (SSC) profile of zebrafish 
Tg(IgM1::LoxP-H2B-mCherry-LoxP-cmyc-eGFP) whole kidney shows four 
cell populations: erythroid, lymphoid, myeloid, and precursor cells. (b) Scatter 
for mCherry expression of cells within the lymphoid gate. (c) Population of 
lymphoid cells gate among all cells isolated from zebrafish kidney of WT and 
Tg(IgM1::LoxP-H2B-mCherry-LoxP-cmyc-eGFP). (Error bar is means + 
SEM, Mann Whitney test, ns, p=0.7727). 
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No obvious abnormality was observed in larvae and adult zebrafish of Tg 
(IgM1::cmyc-eGFP) from F1 to F2. The possible reasons were 1) the 
expression level of cmyc in B cells in this model leads to B cells undergoing 
apoptosis, 2) the expression levels of cmyc driven by IgM1 were not high 
enough for tumorigenesis of B cells. Thus, cells from kidney of F2 Tg 
(IgM1::cmyc-eGFP) were analysed by FACS. The data showed that there 
were barely any GFP+ cells and the percentage of lymphoid cells was lower 




Figure 3.4 FACS analysis of Tg(IgM1::cmyc-eGFP) 
(a) The forward scatter (FSC) versus side scatter (SSC) profile of zebrafish 
Tg(IgM1:cmyc-eGFP) whole kidney shows four cell populations: erythroid, 
lymphoid, myeloid, and precursor cells. (b) Scatter for GFP expression of 
cells within the lymphoid gate. The adjacent laser was used to exclude the 
auto-fluorescence. (c) Population of lymphoid cells gated among all cells 
isolated from zebrafish kidney of WT and Tg(IgM1::cmyc-eGFP). (Error bar is 





This chapter attempted to generate different types of B cell malignancies 
including leukaemia and lymphoma that mimic human cancers by over-
expressing cmyc in B cells at different stages of B cell development. 
 
Despite the evolutionary distance between fish and mammals, dating back 
300 million years, the largely conserved genetic programmes between fish 
and mammals provides a possibility of using zebrafish to establish cancer 
models by transgene manipulation (Zhao et al., 2015, Etchin et al., 2011, 
Mione and Trede, 2010).   
 
As the potent oncogenic roles of cmyc in BL is well established, and many 
successful transgenic cancer models in zebrafish rely on zebrafish promoters 
driving expression of human or mouse oncogenes (Langenau et al., 2003, 
Park et al., 2008a, Patton et al., 2005), zebrafish B cell specific promoter 
IgM1 driven mouse cmyc expression was used to generate B cell lymphoma 
in this project.  
 
Tg(IgM1::cmyc-eGFP) was generated to constitutively express oncogenic 
cmyc in B cells. Meanwhile, Cre/LoxP system was used to generate inducible 
B cell lymphoma models by controlling cell transformation in a temporal 
manner. This inducible system included two transgenes:  the driver line, 
Tg(IgM1::Cre-ERT2) and the effector line, Tg(IgM1::LoxP-H2B-mCherry-
LoxP-cmyc-eGFP). The latter transgene could be used as a B cell reporter in 
this project as they have mCherry labelled B cells. 
 
Zebrafish kidney is a flattened organ and very fragile making it difficult to 
conserve structure during procedures including isolation, fixation. Moreover, 
the strong auto-fluorescence of the kidney increased the difficulty of 
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analysing B cells by fluorescence microscopy.  Therefore, FACS was chosen 
as the method to analyse B cells in these transgenic models. 
 
However, transgenic zebrafish Tg(IgM1::cmyc-eGFP)  did not develop B cell 
malignancies. The FACS analysis showed lymphocyte depletion in head 
kidney of Tg(IgM1::cmyc-eGFP). There were very few green-labelled cells in 
the kidney suspension of Tg(IgM1::cmyc-eGFP) while Tg(IgM1::LoxP-H2B-
mCherry-LoxP-cmyc-eGFP) had much more mCherry-labelled cells in the 
lymphocyte gated population.  The percentages of different cell populations 
in kidney of Tg(IgM1::LoxP-H2B-mCherry-LoxP-cmyc-eGFP) are consistent 
with the literature (Traver, 2004, Chi et al., 2018). These data indicated a 
lack of a detectable B cell malignancy in Tg(IgM1::cmyc-eGFP) Instead cmyc 
over-expression in mature B cells might leads to cell death.  
 
P53 is a well characterised tumour suppressor gene with mutations  
observed in many human cancers (Sherr, 2004, Olivier et al., 2002). 
Moreover, p53 has been shown to regulate cell-cycle checkpoints and cell 
apoptosis (Berghmans et al., 2005, Levine, 1997) When p53 is mutated, cells 
will lack apoptosis and cell-cycle arrest in response to DNA damage, leading 
to accumulation of mutations to cause oncogenesis. Therefore, a p53-/- 
mutant zebrafish (Berghmans et al., 2005) may provide the opportunity for 
cmyc transformed B cells to survive to initiate B cell lymphoma. 
 
The efforts to generate B cell lymphoma models in zebrafish were not 
pursued further as the observations so far clearly indicate the difficulty in live 
imaging early events in B cell transformation in zebrafish kidney due to the 
late appearance of B cells (20dpf) and the anatomy of zebrafish kidney. 
Without the advantages of live imaging, it is not very appealing to generate B 
cell lymphomas for my research purposes given the established and 
relatively well-characterised murine models of B cell lymphoma (Mattarollo et 
al., 2012, Han et al., 2005, Liu et al., 2010, Donnou et al., 2012, Kovalchuk et 





Chapter 4 Generation of zebrafish xenograft models 
of Burkitt’s lymphoma 
4.1 Introduction 
Zebrafish xenograft models have contributed to our understanding of various 
cancer-related phenomena such as invasion, metastasis, angiogenesis, and 
cancer stem cell renewal due to their amenability for imaging and large-scale 
chemical genetic screening (Amatruda et al., 2002, Nicoli and Presta, 2007, 
Yen et al., 2014).  
 
The zebrafish embryo is translucent allowing direct in vivo imaging of 
transplanted tumour cells, less challenging than other xenograft models. 
Therefore, zebrafish embryos are widely used to study tumour cell 
proliferation and metastasis. With the availability of transgenic zebrafish lines 
bearing fluorescently-labelled blood vessels, tumour angiogenesis is also 
being explored in zebrafish xenografts and have shown great potential. 
Significantly, zebrafish and human share common features in their immune 
systems ,in terms of development and cellular diversity, cell types, thereby 
providing a relevant model system to study  interplay between malignant 
cells and the tumour microenvironment (Traver et al., 2003). 
 
Many tumours, especially leukaemia, rhabdomyosarcoma, and melanoma 
have been intensively studied using zebrafish models (Langenau et al., 2005, 
Langenau et al., 2003, Langenau et al., 2007, van der Ent et al., 2014). 
However, there are no published studies of B cell lymphoma models in 
zebrafish. 
 
Burkitt’s lymphoma, with the characteristics of high rate of proliferation and 
extensive apoptosis, as an example of aggressive B cell lymphomas has 
been chosen to study the role of apoptosis in tumour progression in this 
project. Apoptotic cells have been shown to promote and coordinate tumour 
growth, angiogenesis and modulation of tumour-associated TAMs in 
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aggressive B cell lymphomas (Ford et al., 2015). The complex mechanisms 
underlying apoptosis-mediated tumour progression are still unclear, 




This chapter focuses on the generation of zebrafish xenograft models to 
observe the early events in Burkitt’s lymphoma development with the aim of 
revealing possible roles for apoptotic tumour cells in promoting an oncogenic 
tumour microenvironment as suggested by mouse xenograft models. 
 My specific aims: 
1. To establish a temperature that would allow both normal development 
of zebrafish embryos and uninhibited growth, viability and apoptosis 
rate in a human Burkitt’s lymphoma cell line, BL2. 
2. To observe the BL2 cells’ behaviour in the zebrafish host, specifically 
the induction of lymph/angiogenesis. 
3. To determine whether the extent of apoptosis in the transplanted 
inoculum influences BL2 cell growth in zebrafish. 





4.2.1 Identification of a temperature that meets the requirement for normal 
development of zebrafish embryos without significantly affecting BL cell 
proliferation and apoptosis 
4.2.1.1 Assessment of temperature effects on zebrafish development 
Zebrafish embryos were generated by natural mating of adult zebrafish 
according to a standard protocol (Westerfield, 1995a).  
 
Zebrafish were housed at their optimum temperature of 28.5oC for 2.5 days 
then for a further 5 days at various temperatures between 32oC and 35oC 
and the gross morphology of the embryos was compared.  Those kept at 
34oC continued to develop normally (figure 4.1) but when maintained at 
35oC, some showed major deformations of the trunk (not shown).  The size 
of the zebrafish larvae did not show large differences while some fish had 
darker skin, implying that pigment development may be enhanced by high 
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Figure 4.1 Normal development of zebrafish at 34oC from 2.5dpf to 5dpf 
Zebrafish embryos were housed at 28.5oC until 2.5 dpf then some were 
transferred to 34oC for a further 2.5 days. Embryos housed at the higher 






4.2.1.2 Effect of reduced in vitro culture temperature on rates of growth and 
apoptosis of BL cells 	
BL2 cells were transferred from 37oC to 32oC incrementally by reducing the 
temperature by 1 or 2 degree per week. At each temperature (35oC, 34oC, 
33oC, and 32oC), cell’ growth conditions were monitored by trypan blue 
exclusion. 
 
Cells cultured at 32oC died after a week while those at 33oC survived but 
grew slower than at 37oC (figure 4.2). 
	
At 34oC and 35oC the growth rates were slightly lower than those observed at 
37oC (figure 4.2). 33oC, the lowest temperature which allowed BL2 cells to 
divide was chosen to further investigate the impact of reduced temperature 
on cells. The apoptosis-inhibited counterpart of BL2 cells, BL2-bcl2 cells 
showed similar responses to temperature change as they were able to 
proliferate at a lower rate (figure 4.3).	
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Figure 4.2 Proliferation of parental BL2 cells at various temperatures 
	
Cells were adapted to in vitro culture at 33oC by gradually lowering the 
temperature for 4 weeks and their total number counted daily by 
haemocytometer.	Seeding densities were 0.2 x106 cells /ml. 	(Data presented 




Figure 4.3 Proliferation of BL2-Bcl2 transfectants at various 
temperatures. 
Cells were adapted to in vitro culture at 33oC by gradually lowering the 
temperature for 4 weeks and their total numbers counted daily in a 
haemocytomete.  Seeding densities were 0.2 x106 cells /ml.  (Data presented 
are means ± SEM for three independent experiments). 
 
BL cells have a characteristically high rate of spontaneous apoptosis which 
has been suggested to contribute to development of tumours (Ford et al., 
2015). Flow cytometric analysis of the binding of annexin V (AxV) and 
propidium iodide (PI) by the cells was used to assess apoptosis and 
membrane integrity (respectively) before and after exposure to UV radiation 
or the protein kinase inhibitor, staurosporine (Stau).	
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The viability of BL2 cells cultured at 33oC was slightly greater than those 
cultured at 37oC as indicated by the higher proportion of AxV+/PI- cells (fig 
4.4). There were correspondingly fewer cells in early apoptosis as indicated 
by the lower proportion staining for AxV+ but PI-. However >90% of cells 
from both culture conditions were induced into apoptosis by UV irradiation or 
Stau as indicated by AxV binding.  Flow cytometry results showed that the 
majority of BL2 cells growing at 33oC underwent apoptosis after UV or Stau 
treatment which is consistent with that of cells at 37oC (figure 4.4). These 
data showed that when the temperature was reduced to 33oC, cells 




Figure 4.4 Induction of apoptosis of BL2 cells at 33oC	
	
BL2 cells were induced by UV treatment and incubated in serum-free 
medium for 3 hours or were incubated in serum-free medium with 1µM 
staurosporine (Stau) for 3 hours before assessment by AxV/PI. Summary 
graph shows the percentage of viable (AxV-PI-), early apoptotic (AxV+PI-) 
late apoptotic (AxV+PI+) and necrotic cells (AxV-PI+) at 37oC and 33oC. 








































Binding of AxV and PI was also assessed for BL2 cells which over-expressed 
BCL2, a suppressor of apoptosis after UV-irradiation and stimulation with 
staurosporine. These bcl2 transfectants served as control cells in 
transplantation experiments (see later). Less than 20% of these cells could 
be induced to undergo apoptosis when cultured at 37oC but a larger 
proportion was induced at the lower temperature (figure 4.5).	
	
	
Figure 4.5 Commitment to apoptosis by UV or Stau induction can be 
inhibited by bcl-2 overexpression at 37oC and 33oC.	
BL2-bcl2 cells were induced by UV treatment and incubated in serum-free 
medium for 3 hours or cells were incubated in serum-free medium with 1µM 
Stau for 3 hours before assessment by AxV/PI. Summary graph shows the 
percentage of viable (AxV-PI-), early apoptotic (AxV+PI-), late apoptotic 
(AxV+PI+) and necrotic cells (AxV-PI+) at 37oC and 33oC. (Data presented 
are means± SEM of of three independent experiments).	
	
These results indicated that zebrafish develop normally at increased 
temperatures up to 34oC while BL2 cells retained their viability together with 




































This provided a rational basis for the choice of a satisfactory compromise 
experimental temperature at which transplantation studies of BL2 cells into 
zebrafish could be performed.  A temperature of 34oC was chosen, allowing 
BL2 cells to proliferate and undergo apoptosis at rates near to those 
observed at their normal physiological temperature while maintaining healthy 
zebrafish larvae with unimpaired development. This balance is critically 
important when studying the interplay between tumour cells and their host 
environment so as to determine tumorigenic parameters, such as tumour cell 
invasion, metastasis and angiogenesis. 	
	
4.2.2 Construction of BL xenograft zebrafish models 
In order to directly observe tumour cell behaviour in zebrafish embryos, BL2 
cells were fluorescently labelled (figure 4.6). Fluorescent BL2 cells retain the 
properties of parental cells already described, at 34oC. 
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Figure 4.6 Generation of fluorescent-tagged BL cell lines 
(a) BL2 cells were transfected with Lentivirus-cppt-emGFP-opre. (b) BL2-bcl2 
cells were transfected with Lentivirus-cppt-emGFP-opre. (c) BL2 cells were 
transfected with Lentivirus-cppt-IRES-mcherry-opre. (d) BL2-bcl2 cells were 
transfected with Lentivirus-cppt-IRES-mcherry-opre. (Scale bar = 20 µm).	
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As shown in figure 4.7, prior to injecting BL2 cells at 2dpf zebrafish embryos 
were incubated at 28.5oC. Fluorescence labelled BL2 cells were loaded into 
a pulled glass micropipette and the tip of the needle was inserted into the 
yolk sac of zebrafish embryo. The size of the tip was crucial and a sharp 
needle cut in the yolk reclosed immediately without any loss of contents. The 
yolk sac was chosen as the injection site as it has obvious advantages 
including relatively large transplantable cell burden. Moreover, for the 
angiogenesis study, the clear pattern of normal sub-intestinal vessels (SIV) in 
the yolk sac facilitates semi-quantitative detection of tumour induced 
angiogenesis (figure 4.8). 	
	
Zebrafish were observed by fluorescence microscopy at 1hpi to detect the 
labelled cells in the yolk sac and to select ‘clean’ injection embryos (figure 
4.7). ‘Clean’ injected embryos were maintained in at 34oC up to 5dpf when 
tumour formation, invasion and their association with angiogenesis or co-
option of surrounding vasculature in the host were assessed by fluorescence 
microscopy. In order to address lymph/angiogenesis, transgenic zebrafish 
Tg(flk1::mCherry) (Jin et al., 2005) and Tg(fli1::eGFP) (Lawson and 
Weinstein, 2002) were employed. The former labels all blood vessels and the 




Figure 4.7 Schematic illustration of zebrafish xenotransplant lymphoma 
model 
(a) Prior to injecting BL2 cells on 2 dpf, zebrafish were incubated at 28.5oC. 
Fluorescently labelled BL2 cells were injected into the yolk sac. Zebrafish 
were incubated at 28.5oC for an hour for recovery and then observed for the 
detection of a fluorescent cell mass localized at the injection site and to 
confirm a ‘clean’ injection.  Selected xenografts were maintained at 34oC up 
to 5 dpf when images were recorded by fluorescence microscopy and 
confocal microscopy to study lymph/angiogenesis as well as interactions 
between cancer cells and stromal cells. (b) Representative photos of 
zebrafish xenografts bearing BL2-eGFP cells in the yolk sac of 




Figure 4.8 Normal SIV development in zebrafish embryo	
(a) Schematic cartoon representation of SIVs in zebrafish from 2dpf to 3dpf 
(adapted from Stefania Nicoli & Marco Presta, 2007 (Nicoli and Presta, 
2007)) (b) Lateral view of the normally developed SIV plexus of 3dpf 
Tg(fli1::eGFP). Square box indicates the SIVs where the induced 
angiogenesis is observed. (Scale bar = 100 µm)	
 
4.2.3 Loss of proliferative capacity of BL2 cells in zebrafish: no detectable 
angiogenesis or metastasis  
Since 2005 with the first transplantation of human tumour cells into zebrafish, 
the first and possibly most reported cancer cell lines in zebrafish xenograft 
models are highly tumorigenic melanoma cells (Lee et al., 2005). Therefore a 
human malignant melanoma cell line (A375) was used to assess the 
sensitivity of the putative zebrafish lymphoma model described here. A375 
cells were labelled with Cyan or eGFP and referred to as M-eGFP or M-cyan 
here. The melanoma cells proliferated at the injection site and metastasized 
in the zebrafish after 3dpi and induced angiogenesis after 1dpi (fig 4.9). This 
is consistent with the literature and indicates the potential for engraftment of 
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human tumours into zebrafish (Lee et al., 2005, Nicoli et al., 2007, Haldi et 
al., 2006).  This also confirmed that this optimised putative zebrafish 
lymphoma model was suitable to investigate the tumour cell proliferation, 





Figure 4.9 Transplanted human melanoma cells can form tumours in 
zebrafish 
(a) Melanoma cells proliferated in zebrafish up to 3 dpi. (b) Melanoma cells 
induce angiogenesis (branches from SIV) within 1dpi in zebrafish 
Tg(fli1::eGFP). Arrow indicates the injected melanoma cells. (c) Melanoma 
cells metastasise and form tumour clogs in the tail of the Tg(flk1::mCherry) 
zebrafish favouring the circulatory loop at the end of the tail at 3dpi. Arrows 




BL2 cells however, did not proliferate in zebrafish and did not survive longer 
than 4 days. When 50 cells were injected, none could be detected at 2dpi 
while for injections of 200 to 500 cells, most of the xenografts have no 
detectable BL2 cells at 3dpi. When the injected cells were increased to 1000 
cells per fish, 90% of xenografts still bore BL2 cells at 3dpf but lacked BL2 
cells at 4dpf.Thus, the length of time in which they could be detected was 
associated with the implanted cell number.  Different injected cell numbers 
were chosen for different aims in this project. For the angiogenesis assay, 
considering the increasing complexity of vessels in the trunk of embryos, it 
was desirable to induce angiogenesis in a relatively shorter time by 
increasing the injected cell number. Meanwhile, it was crucial to limit the size 
of injected cells and not to disturb the development of SIVs by physical 
stress. Therefore, 200 to 500 cells per fish the injected cells were chosen for 
the following angiogenesis assays. Zebrafish embryos bearing 200 or 500 BL 
cells in the yolk sac were observed daily until 3dpi and neither angiogenesis 
nor lymphoangiogenesis were detected (figure 4.10). Most of xenografts 
bearing 500 cells (left column in figure 4.10) had detectable tumour cells until 
3dpi while most of xenograft bearing 200 cells (right column in figure 4.10) 
had detectable tumour cells until 2dpf. As shown in the figure, the size of 
transplanted cells did not decrease in the first 24 hours and started to 
decrease slowly until the final 24 hours before the cell mass disappeared. 
These observations suggested that the transplanted BL cells survived in the 
zebrafish until lack of certain factor(s) impacted on their viability, since most 




Figure 4.10 Transplanted BL2 cells did not induce lymph/angiogenesis	
Representative fluorescence images represent zebrafish at 2 hpi, 1 dpi, 2 dpi 
and 3 dpi of injection of about 500 BL2-GFP cells into Tg(flk1::mCherry) (left 
lane, BL2-GFP/flk1::mCherry) or 200 BL2-mCherry cells into Tg(fli1::eGFP) 
(right lane, BL2-mCherry/fli1::eGFP). Arrows indicate the injected cells. No 
detectable lymph/angiogenesis in Tg(flk1::mCherry) and Tg(fli1::eGFP). 
(Total over 50 samples each group from 3 independent experiments were 
observed. Scale bar = 100 µm)	
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To further investigate cell behaviour, day-to-day observations were employed 
to study the activity of BL cells in zebrafish. BL2 cells were dying in zebrafish 
and did not survive over 4dpi irrespective of cell number transplanted. This 
survival assay used 1000 cells as transplanted cell number. Fluorescence 
photos of injected cells were taken from 1hpi daily until no detectable signal 
using the same magnification and the size of cells was calculated using 
Image J for two-dimensional area quantification (figure 4.11a). The 
proliferation of cells was assessed by phosphor-histone-3 (Histone-3) and all 
cells lost their proliferative capacity at 3dpi (figure 4.11b). 	
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Figure 4.11 Transplanted BL2 cells lost proliferative ability	
(a) BL2 cells were dying in zebrafish (Data presented are means± SEM of 
of three independent experiments. Mann Whitney test, *p<0.05, **p<0.01). 
(b) Histone-3 staining shows no proliferating BL2 cells from 3dpi in 
zebrafish. (Scale bar = 100 µm).	
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Despite transplanted cell viability loss by 3dpi and disappearance no later 
than 4 dpi, there was variability between xenografts. Therefore, time-lapse of 
cells in zebrafish were recorded and the results demonstrated that 
neighbouring BL cells died synchronously within 40 minutes (figure 4.12) and  
the whole cell mass disappeared. These data showed that the transplanted 
cells tended to die in a synchronous manner, which indicated that the failure 
of BL2 engrafted in zebrafish might be due to the lack of certain survival 
factor(s) or necessary tissue structure rather than the nutrient deficiency. 	
	
Figure 4.12 Neighbouring BL cells die synchronously	
In a BL2 cells xenograft embryo, time-lapses of focused three neighbouring 
shows all three viable cells start to die synchronously and loose their 
fluorescent signals in 40 minutes. (Scale bar = 50 µm).	
	
Since data so far had indicated the importance of environmental factors in 
supporting BL cell viability in zebrafish, other niches might promote  BL cell 
survival in zebrafish. Therefore, most of the reported injection sites in 
literature were tested to determine whether there was a suitable niche for BL 
cell survival and proliferation in zebrafish (figure 4.13) and in all the xenograft 
sites tested, BL2 cells did survive over 4dpi. Injections sites included the yolk 
sac, the pericardial cavity, the brain, in the otic space, the perivitelline space 
(figure 4.13, a to e). Cells were also injected into circulation through duct of 
cuvier to see whether cells managed to locate at a favourable place to 
survive and injected cells reached posterior blood island within 15 minutes 
(figure 4.13, f).  Some cells remained within caudal hematopoietic tissue 




Figure 4.13 Representative photos of transplantation of cells into 
zebrafish	
Cartoon provides the schematic depiction of injected sites of transplantation 
of BL2-eGFP cells in Tg(flk1::mCherry  a. Cells transplanted in the yolk sac, 
b. Cells transplanted in the pericardial cavity, c. Cells transplanted in the 
brain, d. Cells transplanted in the otic space, e. Cells transplanted in the 
perivitelline space. f. Cells transplanted in the circulation. Arrows indicate the 
injected cells.  (zebrafish head to left of images in a,b,d,e,f , dorsal view of 
zebrafish head in image c. Scale bar = 100 µm )	
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4.2.4 BL cells resistant to apoptosis demonstrated reduced capacity to 
survival in zebrafish 
The transplanted BL2 cells cannot survive longer than 4dpi in zebrafish 
despite various injection sites including yolk sac, brain, perivitelline space, 
pericardial cavity and circulation. Even so, the yolk sac maintained cells 
longer than other sites, possibly due to the higher cell burden capacity. 
	
The mouse xenograft models of BL established by our group demonstrated 
that apoptosis-suppressed BL cells showed an equivalent or slightly slower 
growth trend as compared to their ‘‘pro- apoptotic’’ parental counterparts 
(Ford et al., 2015).  To determine whether apoptosis in lymphoma cells 
affects tumour growth in zebrafish, parental BL2 cells and their apoptosis-
inhibited counterpart BL2-bcl2 cells were transplanted into the yolk sac of 
zebrafish. 1000 cells were chosen to transplant for these experiments aiming 
to achieve long survival without compromising zebrafish viability. For each 
experiment, approximately 20 embryos for each group were analysed 
including 1) embryos injected with medium only, 2) BL2 cells transplanted 
and 3) BL2-bcl2 cells transplanted were examined.  All embryos survived and 
grew healthily during the experimental period. 90% BL2 transplanted 
zebrafish had visible tumour mass while only 55% BL2-bcl2 transplanted 




Figure 4.14 B lymphoma cells 
resistant to apoptosis 
demonstrated reduced capacity 
to survive in zebrafish 
Growth of BL2 cells and BL2-bcl2 
transfectant in fish at 34oC 3dpf. 
(Data presented are means± SEM 
of three independent experiments, 
Mann Whitney test, p**=0.0079)	
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4.2.5 Macrophages are modulated by apoptotic BL cells  
Within the BL umour microenvironment, macrophages contribute to a 
significant proportion of the tumour mass and unbiased "in situ 
transcriptomics" analysis-gene expression profiling have demonstrated 
apoptotic tumour cells modulate macrophages to promote a tumour growth 
phenotype in mouse models (Ford et al., 2015).  
 
To investigate whether apoptotic tumour cells could polarise macrophages to 
a pro-tumour growth phenotype, peripheral monocyte derived macrophages 
(PMDM) were stimulated by apoptotic BL2 cells (referred as M2) and then 
co-injected with BL2 cells into zebrafish embryos.  PMDM were treated with 
50ng/ml LPS + 20ng/ml IFN and this treatment (referred as M1) was 
generally considered to activate macrophages to M1 subtype.  Another group 
of PMDM underwent similar culture procedures without additional stimuli  
(referred as M0).  
 
Macrophages with different polarisation were co-injected with 200 of BL2 
cells into the YS of zebrafish. The ratio of macrophage and BL cells was 1 : 
1,  while 200  BL2 cells alone were injected as a control.  
	
To see whether and how endogenous macrophages actively interact with 
injected tumour cells, I used transgenic line Tg(mpeg1::mCherry/tnfα::eGFP) 
in which macrophages express red fluorescent protein and when pro-
inflammatory activated can also express fluorescent protein green (Nguyen-
Chi et al., 2015) as TNFα (tumour necrosis factor alpha) is considered as a 
marker of M1 macrophages (Eisenman et al., 2015, Fiers, 1991). 	
	
The xenografts were examined at 2hpi, 1dpi and daily until either injected 
cells disappeared or fish died. Xenografts showed no significant difference in 
their interaction with endogenous macrophages and no TNFα activation in 
macrophages was seen in all groups (figure 4.15 a). The xenografts of all 
groups had no mortality in the first 48 hours (figure 4.15 a, b) and the 
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xenografts bearing the mixture BL2 and M2 macrophages showed high 
mortality at 3dpi while larvae in other group showed no significant viability 
change (figure 4.15b).  As shown in figure 4.16 a, BL2 cells co-injected the 
M2 macrophage tended to spread along the outline of YS while the other 
group of BL2 cells maintained as a single colony at the injection site at 2dpi. 
This altered behaviour of BL2 cells may account for the high mortality of 
xenografts at 3dpi (figure 4.15 b). 	
	
At 3dpi, in the group of BL2 + M1 macrophage co-injection, only about 5% of 
the xenografts had live BL2 cells while the 72% of the BL2 + M0 macrophage 







Figure 4.15 Apoptotic BL cells polarised macrophages facilitate 
xenograft BL2 cells survival in zebrafish larvae	
a. Representative confocal images of Tg(mpeg1::mCherry/TNFα::eGFP) 
larvae bearing BL2 cells, BL2 cells with M0 macophages, BL2 cells with M1 
macrophages from 1dpi to 4dpi and BL2 cells with M2 macrophages from 
1dpi to 3dpi.  At each dpi, upper panel shows the GFP channel and lower 
panel shows the overlay of GFP channel and mCherry channel. Stars 
indicate the injected cells. All the images except ‘BL2 cells with M2 at 3dpi’ 
are focused at yolk sac of zebrafish and ‘BL2 cells with M2’ show the whole 
fish body (Scale bar = 200 µm). b. Survival of xenografts from the day of 
injection to 3dpi. c. The percentages of living xenografts still have 
transplanted tumour cell at 3dpi (Data presented are means± SEM of three 
independent experiments, **p<0.01, ****p<0.0001, one-way ANOVA).	
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4.3 Discussion 
The translucency of embryos and availability of many transgenic reporter 
zebrafish   provides a clear advantage in studying early events in tumour 
angiogenesis and metastasis by allowing the visualization of fluorescently 
labelled human tumour cells and interaction with stromal cells (Lee et al., 
2005, Haldi et al., 2006, Nicoli et al., 2007a, Marques et al., 2009, Tobia et 
al., 2011). This chapter focused on establishing a robust and reliable 
zebrafish model to study tumour cell behaviour and key events in tumour 
growth including angiogenesis and metastasis of B cell lymphoma with the 
aim of identifying mechanisms underlying apoptosis promotion of tumour 
growth. 
 
In order to assess proliferation and migration of injected tumour cells in 
zebrafish, we generated fluorescent-tagged BL cell lines. And with the 
availability of other reporter lines allowing  intravital imaging of cancer growth 
events, such as the fluorescent vascular system allowing the observation of 
lymph/angiogenesis induced by engrafted tumour cells; or macrophage 
reporter lines allowing the study of the interaction of macrophages and 
tumour cells. 
	
The first part of this chapter was to optimise xenograft models for BL cells 
including the incubation temperature, the injection day, the injection site and 
the injection cell number dependent on the research purpose.	
	
Zebrafish are normally maintained at 28.5oC while human BL cells are 
cultured at 37oC.The incubation temperature of xenograft zebrafish in the 
literature varied from 31oC to 37oC (Lee et al., 2005, Haldi et al., 2006, Nicoli 
and Presta, 2007).  It was desirable to assess the highest temperature 
tolerance of zebrafish embryos and biological properties of BL2 cells at lower 
temperatures in order to establish a suitable compromised temperature.	
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An obvious problem in establishing xenograft human cancer models in 
zebrafish is that zebrafish are usually maintained at 28oC and 9 degrees 
lower than that of mammalian cells. Studies on temperature effects on 
zebrafish embryo development are sparse. In the existing zebrafish xenograft 
models, the optimal incubation temperatures usually vary from 31oC to 37oC 
depending on the purpose of experiments and type of tumour cells used 
(Jung et al., 2012, He et al., 2012, Berman et al., 2012, Zhao et al., 2011, 
Tobia et al., 2011, Pruvot et al., 2011, Corkery et al., 2011, Moshal et al., 
2010, Marques et al., 2009, Nicoli et al., 2007, Nicoli and Presta, 2007, Haldi 
et al., 2006, Lee et al., 2005). In this work, with the aim of mimicking the BL 
microenvironment, the temperature should be suitable for BL cells to 
proliferate and to maintain the parental phenotype of BL tumour cells. Growth 
kinetics and apoptosis assays were carried out at 35oC, 34oC, 33oC, 32oC 
and cells grew normally at 35oC, 34oC, 33oC with reasonable decreased 
growth rates while cells incubated at 32oC failed to proliferate. We also 
incubated zebrafish at different temperatures and observed their viability and 
morphology. Zebrafish seemed to grow healthily at 34oC when some showed 
abnormal sharps maintained at 35oC. Therefore, 34oC represented a rational 
compromise: it allowed cancer cells to proliferate while maintaining zebrafish 
larval health and development, which is important when studying the 
interplay of tumour cells and tumorigenic parameters, such as tumour 
formation, invasion, metastasis, especially angiogenesis and with the 
advantage of highly regulated pattern of blood vessels in zebrafish (Isogai et 
al., 2001). 
 
Various tumour cells and different transplantation sites of tumour cells into 
zebrafish embryo to study different aspects of tumour progression have been 
described in the literatures (Konantz et al., 2012, Wertman et al., 2016, Nicoli 
and Presta, 2007). For angiogenesis studies, the yolk sac and perivitelline 
space are the most popular sites. The primary embryonic vascular plexus of 
dorsal aorta (DA) and axial vein (AV) are formed by vasculogenesis by 
approximately 24hpf and by 3dpf, angiogenic vessels including the SIV have 
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formed. The organised pattern of SIVs make it a suitable model to study 
induced sprouting. 
 
Optimal conditions for cell transplantation were established and these 
generated a reproducible xenotransplant zebrafish model using human BL 
cells. Parameters including the site and stage for transplantation, number of 
injected cancer cells, incubation temperature were optimised.  Specifically, 
yolk sac can bear more cells than other injection sites. At 2dpf, the body plan 
of zebrafish is completely formed reducing the probability of passive 
transport during gastrulation.  Up to 1000 cells within 10nl causes little 
surgical damage to zebrafish embryos. To avoid spatio interference of the 
SIVs development, 200 to 500 cells were used for angiogenesis assays and 
for proliferation studies up to 1000 cells were employed in this project.  
	
BL cells were transplanted into the zebrafish yolk sac at 2dpf and checked 
daily until 5dpf. There was no detectable lymph/angiogenesis and no obvious 
metastasis in xenograft models. One possible explanation for no detectable 
lymph/angiogenesis is that BL cells are not aggressive enough to induce 
lymph/angiogenesis in this zebrafish model. Although there was some 
variability among fish, the cells were no longer detectable in xenografts at 
4dpi. Engrafted BL cell death was measured by the fluorescent signals daily 
followed by immunohistochemistry experiments using phospho-histone H3. 
BL cells lost their ability to proliferate and just survived until they died in a 
synchronous manner. The lower injected cell number with decreased survival 
time indicate the failure of proliferation of BL cells in zebrafish might be 
caused by missing key growth-supporting factor(s) rather than nutrient 
deficiency. It is well known that zebrafish has no adaptive immune response 
at least till 10 dpf and the disappearance of BL cells happened in a relative 
short time. The most reasonable explanation is that BL cells started to 
undergo extensive apoptosis during this period due to the lack of certain 
factor(s) and were cleared by professional phagocytes such as neutrophils, 
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macrophages which develop at an early stage in zebrafish (Meeker and 
Trede, 2008, Renshaw and Ingham, 2010, Traver et al., 2003).  
 
In other xenograft zebrafish models to study angiogenesis, more malignant 
tumour cells, mainly melanoma (Zhao et al., 2011, Haldi et al., 2006), or 
tumour cell lines that express the angiogenic FGF 2 and/or VEGF were used. 
I also used a human melanoma cell line (A375) as  “positive control” to 
exclude the possibility of technical issues.  Melanoma cells proliferate and 
induce angiogenesis in zebrafish. From observations of cell morphology and 
behaviour of BL2 cells and melanoma (A375) cells, it is easy to notice 
significant differences in  that BL cells stick together and remain at  the 
injection site while melanoma cells are much mobile and able to survive  and 
even proliferate as single cells. Different tumour cells have their own growth 
patterns in human and this also is true for zebrafish.  
	
The survival of BL cells in zebrafish was closely correlated with the injected 
tumour cell numbers and they seemed to prefer to stick with each other 
implying the supportive roles of tumour cells for each other. Moreover, the 
implanted tumour cells died in a synchronous manner and this may be 
caused by the lack of certain growth factor(s) or environmental cue(s) rather 
than the deprivation of nutrients in the YS.  	
 
In comparing the survival of BL2 and BL2-bcl2 cells, BL cells resistant to 
apoptosis demonstrated reduced capacity for survival in zebrafish indicating 
the pro-oncogenic role of apoptotic tumour cells.  
	
Therefore, the next step was to provide a possible supportive player which 
might reveal a possible mechanism for supporting tumour growth. The 
supportive mechanisms of apoptosis might include direct interaction, 
secreted molecules, released vesicles and regulation of stromal cells in the 
tumour microenvironment. One possible candidate is the most abundant non-
malignant cell population observed in Burkitt’s lymphoma tumours (Wright, 
 97 
1963). TAMs, which are attracted into the tumour niche and activate multiple 
pro-tumour pathways in mouse xenografts in unbiased ‘‘in situ 
transcriptomics’’ analysis (Ford et al., 2015). Despite the well-accepted 
notion of supportive tumour growth of TAMs, the details of how macrophages 
are polarised and how certain subtype influence the tumour cells behaviour 
are not fully understood.   
 
PMDM were polarised by 1) apoptotic tumours, 2) traditional pro-
inflammatory macrophage stimulation of cytokines (LPS and IFN) (Dale et 
al., 2008) 3) no external stimulation. Macrophages after different treatments 
were mixed with BL2 cells and transplanted to 2dpf embryos. To take 
advantage of the zebrafish model, I used transgenic fish Tg 
(mpeg1::mCherry/tnfα::eGFP) with macrophage fluorescent-tagged with  
cells turning green if expressing TNFα. When observed by fluorescent 
microscopy, there were no significant differences in macrophage numbers or 
morphologic features surrounding the injected cells. The reasons for this may 
lie in 1) at the selected time points there were no differences in the numbers 
and morphology of macrophages surrounding injected tumour cells, 2) the 
sensitivity of the fluorescent microscopy used cannot capture the differences 
between macrophages. However, the subtypes of macrophages modulated 
the tumour cell survival and behaviour differently. Macrophages polarised by 
apoptotic tumours gave the BL2 cells’ ability to survive as individuals even 
though this time length was quite short and cells died shortly after. The 
decreased survival of BL2 when co-injected with M1 was consistent with the 
known function of pro-inflammatory macrophages drive tumour cell death 
(Mosser and Edwards, 2008, Edwards et al., 2006, Li et al., 2018).  
 
In conclusion, engrafted BL cells cannot proliferate in zebrafish and have no 
ability to induce lymph/angiogenesis. Reduced survival of apoptosis-inhibited 
human BL cells in zebrafish indicate the possible oncogenic properties of 
apoptotic BL cells. This model provides opportunities to dissect the 
mechanisms underlying oncogenic roles of apoptosis as well as the 
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signalling pathways that may be involved by co-injection of possible 
candidates with BL cells. One of the most promising candidates, 
macrophages, which are potent in a BL tumour microenvironment, was 
further investigated in this established model. Results indicated that 
macrophages could be polarised by apoptotic tumour cells and affect tumour 
cell behaviour and viability of xenografts.    
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Chapter 5 Pro-tumour growth role of apoptosis 
induced EVs (Apo-EVs) in B cell lymphoma 
5.1 Introduction 
The zebrafish embryo offers distinct advantages for studying aspects of 
tumorigenesis in vivo, in particular, angiogenesis and metastasis. This is 
mainly due to transparency of the embryo and the availably of fluorescent-
labelled blood vessel reporter transgenic lines.  
 
Various tumour cell types, such as melanoma cells (A375, WM-266-4, B16-
BL16), ovarian carcinoma cells (MDA-MB-435, OVCAR8), colorectal cancer 
cells (ATCC), and glioma cells (U87) have shown the potential to proliferate, 
metastasise or induce angiogenesis in zebrafish (Konantz et al., 2012, 
Veinotte et al., 2014). However, BL cells do not form tumors in zebrafish 
possibly due to lack of essential growth and survival factor(s) as 
demonstrated by the results in chapter 4. The present chapter presents the 
results of experiments designed to identify possible candidate micro-
environmental mechanisms in BL.   
 
Constitutive high rates of apoptosis in BL foster the accumulation of TAMs  
(tumour associated macrophages), giving rise to the hallmark ‘starry-sky’ 
histological picture. Apoptosis-suppressed Bcl2-expressing BL populations 
demonstrated constrained proliferation in a mouse xenograft model, which 
suggests apoptotic cells could promote BL cell growth through recruitment of 
tumour-promoting TAMs (Ford et al., 2015). In situ transcriptomics analysis 
of TAM from BL indicates that TAMs are activated in a variety of ways to 
promote tumor growth (Ford et al., 2015). Furthermore, the reduced capacity 
of apoptosis-inhibited BL2-bcl2 cells to survive in zebrafish compared to their 
apoptosis-competent parental counterparts supports the notion that 




EVs appear to be released continuously from cancer cells and their release 
is increased by various stimuli.  Several studies have shown that the 
molecular signature of EVs is characteristic of their cell of origin and is 
modulated by the type of stimulus suggesting that the activation regulates the 
non-uniform distribution of various contents compared to their originating 
cells and is closely associated with functions.  
 
In the Gregory group, previous work has shown that EVs from apoptotic BL 
cells, called Apo-EVs contain higher level of B cell surface markers (CD19 
and CD20), apoptosis associated proteins, DNA and RNA than EVs from 
viable tumour cells (Patience, 2016) (unpublished data).  Furthermore, the 
presence of matrix metalloproteinases, MMP2 and MMP12 in Apo-EVs 
suggests the possibility that they may play regulatory roles in angiogenesis 
that is further confirmed by preliminary in vitro human umbilical vein 
endothelial cell (HUVEC) angiogenesis assays (Patience, 2016). It is 
possible that EVs from apoptotic BL2 cells can modulate the activation of 
TAM and drive angiogenesis which in turn promotes BL2 cell survival in a 
zebrafish larval model. 
 
5.1.1 Aims 
The hypothesis underlying this chapter is that the EVs released from 
apoptotic BL cells (Apo-EVs) modulate host macrophages and promote 
angiogenesis which in turn promotes BL2 growth in vivo.  
My specific aims:	
1. To determine the profile of apoptosis-mediated EV release	
2. To compare the pro-angiogenic effects of Apo-EVs with EVs obtained 
from non-apoptotic BL cells stimulated in vivo 
3. To compare the pro-angiogenic effects of secretome from apoptotic 
BL cells and Apo-EVs with secretome obtained from non-apoptotic BL 
cells stimulated and non-Apo-EVs in vivo 





5.2.1 Characterisation of EVs released from B cell lymphoma cells 
In Chapter 4, results showed that both staurosporine and UV treatments 
were capable of inducing apoptosis in BL2 cells while BL2-bcl2 cells did not 
undergo apoptosis due to their expression of BCL2.  To generate apoptosis 
related EVs (Apo-EVs), BL2 cells were induced to undergo apoptosis by UV 
treatment.  EVs from UV-treated BL2-bcl2 cells were used as the control 
since their production is not through apoptosis. Here I use non-Apo-EVs to 
describe the EVs from BL2-bcl2 cells after UV treatment. 
Firstly, the time course of apoptosis after UV treatment was studied.  Cell 
death was assessed by the exposure of PS on the outer membrane by AxV 
and membrane integrity was assessed by PI. Apoptotic cells were measured 
by AxV+PI- staining and the percentage of apoptotic cells (AxV+PI-) reached 
a peak at 4 hours post UV treatment (figure 5.1a). At 4 hours post UV 
treatment, the apoptotic population was normally between 60% and 80%.  
When the culture time was increased to 6 hours, the percentage of apoptotic 
cells (AxV+PI-) showed a decreasing trend and the population of late 
apoptosis (AxV+PI+) increased by over 20%. Therefore, BL2 cells at 4 hours 
after UV treatment were chosen as the provider of Apo-EVs. Meanwhile, 
BL2-bcl2 cells were treated and assessed by the same procedure. The 
results showed that 4 hours after UV treatment, only a very small percentage 
of BL2-bcl2 cells underwent apoptosis (less than 5%) (figure 5.1b) and 
therefore was a suitable control for apoptotic cells.	
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 Figure 5.1 UV treatment timecourse of BL cells	
(a) Flow cytometry for annexin V (AxV) and propidium iodide (PI) showing 
UV-irradiation induces apoptosis in BL2 parental cells and the apoptotic 
population increases until reaching its peak at 4 hours post treatment.  (b) 
Flow cytometry for annexin V (AxV) and propidium iodide (PI) showing UV-
irradiation barely induces apoptosis in Bcl-2-expressing BL2 cells. (Mean ± 
SEM of three independent experiments).	
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For all the Apo-EVs preparations in the presented data, the percentage of 
apoptotic BL2 cells (AxV+PI-) was monitored to make sure the percentage of 
apoptotic cells was above 60 % while the late apoptotic population (AxV+PI+) 
did not exceed 20 % and the percentage of necrosis (AxV-PI+) did not 
exceeded 5 %. 	
	
EVs released from BL2-Bcl2 cells that had been treated by UV and gone 
through similar isolation procedures were used as the control representing 
EVs produced from non-apoptotic cells (non-Apo-EVs). Isolated Apo-EVs 
and non-Apo-EVs were measured by nanoparticle tracking analysis (NTA). 
NTA has been shown as a method to accurately determine EV size and 
concentration in our group. Although UV treated BL2-Bcl2 cells also released  
non-ApoEVs, the NTA results demonstrated that significantly more EVs 
produced by UV treated BL2 cells which correlated with increased apoptosis 
of BL2 cells (figure 5.2a). Furthermore, NTA also demonstrated a different 
size profiles between Apo-EVs and non-Apo-EVs (figure 5.2b). 	
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Figure 5.2 Production of EVs by BL cells is apoptosis associated	
 (a) Nanoparticle tracking analysis (NTA) showing increased release of EVs 
from BL2 cells in line with increased apoptosis (Mean ± SEM of three 
independent experiments). (This work was performed by Margaret Paterson 
in our group). (b) NTA size profiles demonstrate different size profiles 
between Apo-EVs (blue line) (EVs from BL2 cells 4 hours post UV treatment) 
and those from bcl2-transfected BL2 cells 4 hours post UV treatment (orange 




5.2.2 Apo-EVs induce angiogenesis in zebrafish  
Zebrafish embryos provide a convenient model to study angiogenesis. At 2.5 
dpf, the zebrafish body plan has fully developed and SIVs grow in a tightly 
organised fashion.  Based on the findings of chapter 4, the yolk sac of  2.5 
dpf Tg(fli1::eGFP) zebrafish was chosen as the injection site of EVs. Induced 
branches from SIVs was observed at 24 hpi with stereo-fluorescent 




Figure 5.3 Schematic illustration of zebrafish model for EVs-induced 
angiogenesis assay 
EVs were injected into the yolk sac at 2.5dpf and blood vessel pattern were 
observed 24hpi. Zebrafish were kept at 28.5oC.   	
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Initially, a 3-Step Differential Centrifugation Method (details in chapter 2) was 
used to obtain Apo-EVs and cell number was used as the reference for 
quantifying Apo-EVs. Approximately 20nl of EVs from 80x106 UV treated BL2 
cells in 100µl DPBS were injected to assess the pro-angiogenic functions of 
Apo-EVs. EVs from UV treated BL2 cells were injected into the yolk sac of 
GFP-labelled vessel zebrafish Tg(fli1::eGFP). At 24 hpi, 30% of EV 
xenografts showed induced branches and 5% of xenografts exhibited 





Figure 5.4 Apo-EVs modulate angiogenesis in zebrafish 
(a) Representative images of SIVs following different treatment. Arrows 
indicate observation sites. (b) Statistical anaysis shows promotion of 
angiogenesis by Apo-EVs. Xenografts of Apo-EVs show about 35% 
branches with a significant difference from mock controls (Mean ± SEM of 




These preliminary observations showed the EVs from apoptotic BL2 can 
induce angiogenesis in vivo. To further confirm that this pro-angiogenic 
function was Apo-EV specific, effect of non-Apo-EVs were evaluated in 
subsequent experiments. The isolation method for EVs was continually 
optimised in our group and the gentle filtration method (details in chapter 2) 
was shown to produce EVs with high consistency and integrity.  Therefore, all 
the subsequent EVs experiments used filtration method.  Furthermore, as 
shown in figure 5.2, the number of EVs was related to the number of 
apoptotic cells and apparently the same number of BL2-bcl2 cells produced 
much less EVs by the same treatment. Therefore, for the comparison of EVs 
from BL2 and BL2-Bcl2, I used the number of EVs rather than parental cell 
number as the standard for injection purposes. To exclude possible 
angiogenic effects of soluble molecules released by apoptotic BL cells, EVs 
were purified by 300kDa ultrafiltration before the angiogenesis assay. I tried 
different amounts of EVs and found that 107 particles/fish was a suitable 
amount. The sprouting from zebrafish SIVs was detected and quantified 
approximately 24hpi (figure 5.5). 
 
Control zebrafish were injected with media under the same treatment and 
barely induced branches from SIV (figure 5.5 a i). Apo-EVs induced on 
average over 1.5 branches per fish while non-Apo-EVs induced slightly over 
0.5 branch per fish (figure 5.5 b).  The pooled data presented here clearly 
indicated that EVs released from apoptotic BL cells have a significantly 
higher ability to induce angiogenesis (figure 5.5). 	
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Figure 5.5 BL2 Apo-EVs have significantly higher ability to induce 
angiogenesis in zebrafish Yolk Sac xenografts  than  non-Aop-EVs	
(a) Representative images of SIVs with or without induced branches in 
zebrafish yolk sac. i represents no branches. ii represents single branches. iii 
represents multiple branches.   (b) Branches from SIV of each EVs-injected 
zebrafish were calculated. Statistical analysis shows promotion of 
angiogenesis by EVs with a significant higher ability by Apo-EVs. The control 
represented zebrafish injected with DPBS. Data here are pooled from three 
independent experiments with each group including at least 30 samples. 
(Mean ± SEM. Mann Whitney test, **p=0.001, ***p=0.0005, ****p<0.000, 
Scale bar =100 µm.)	
 
As mentioned previously, soluble molecules are released by apoptotic BL 
cells as well as EVs and both may have angiogenic effects. To test this 
theory, secretome from BL2 cells and their EVs, BL2-bcl2 cells and their EVs 
were collected and injected into zebrafish. Products from culture media 
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collected by the same procedure were used as control. Secretome from 
different groups were adjusted to 0.25 mg/ml and volumes were adjusted to 
2nl per embryo, equivelant to 500 pg of secretome was injected into each 
zebrafish. Secretome secreted from BL2 cells and their EVs after UV 
treatment, named Apo-S, showed an ability to induce branches from SIVs. 
Secretome from BL2-bcl2 cells and their EVs after UV treatment, named 
non-Apo-S, showed reduced angiogenesis compared to their apoptosis 
counterparts  (figure 5.6 a). To text whether the protein products are, at least 
partially responsible for the pro-angiogenic effect, proteins of secretome from 
BL2 cells and their EVs was inactivated by stardard heat treatment. The 
ability of Apo-S to induce branches from SIVs in zebrafish was reduced after 




Figure 5.6 Secretome from BL2 cells promote tumour angiogenesis	
(a) Secretome secreted from BL2 cells and their EVs (Apo-S) showed an 
ability to induce branches from SIVs in zebrafish. Reduced angiogenesis was 
observed in apoptosis-suppressed xenografts of secretome from BL2-bcl2 
cells and their EVs (non-Apo-S). Products from culture media collected by 
the same procedure were used as control. Each sample in three groups 
contains 500 pg of secretome.  (b) The pro-angiogenic ability of Apo-S was 
reduced after standard heat treatment (Apo-S HT). (Data here are pooled 
from three independent experiments with each group including at least 30 
samples.  Mean ± SEM, Mann Whitney test, * p<0.05, **p=0.0011)	
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5.2.3 Macrophages are activated and polarised by Apo-EVs in zebrafish 
Macrophages have been closely associated with tumour angiogenesis (De 
Palma et al., 2017, Sica and Mantovani, 2012). However, due to their high 
plasticity and versatility, the exact subsets for certain functions and the 
mechanisms underling their activation and polarisation still remain unclear. 
To determine whether Apo-EVs promote angiogenesis through modulation of 
macrophages, I used transgenic line Tg(mpeg1::mCherry/tnfα::eGFP). 
 
In Tg(mpeg1::mCherry/tnfα::eGFP) larvae, TNFα are not activated in 
macrophages as there are no GFP signals  in mCherry+ cells  (figure 5.7 a). 
EVs and control solution (media underwent the same treatment) were 
injected into YS as described before.  Macrophages in the YS (as indicated 
by white box in figure 5.7 a) were observed 1 day after the EVs injection. As 
shown previously, at 1 dpi of EVs, Apo-EVs showed significantly higher 
ability at inducing angiogenesis (figure 5.5). At the same time point, Apo-EVs 
impacted on macrophage morphology and TNFα activation differently from 
non-Apo-EVs and control (mock control is media underwent the same 
treatment) (figure 5.7 b). Quantification of macrophages in the YS showed 
that the numbers of macrophages in the injection sites were not increased in 
EVs injected zebrafish while the phenotype of macrophages showed 
significant differences (figure 5.7). Some cells are activated to express TNFα 
in Apo-EVs, non-Apo-EVs, media injected groups but not HBSS injected 
group and intact zebrafish (figure 5.7.c). Interestingly, non-Apo-EVs and 
media activated TNFα expression mostly in macrophages while Apo-EVs 
activated much less TNFα expression in macrophages (figure 5.7.d). Nearly 
50% of macrophages in the injection site of non-Apo-EVs injected group 
expressed TNFα while only about 4% of macrophages in the injection site of 
Apo-EVs injected group were expressing TNFα (figure 5.7.e). These results 
showed Apo-EVs impacted on the macrophages not by recruiting them but 




Figure 5.7 Macrophages respond differently upon Apo-EVs and non-
Apo-EVs	
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(a) Tg(mpeg1::mCherry/tnfα::eGFP) larva exhibits mCherry+ macrophages. 
The green fluorescent signals in the back head and auns a s well as auto-
fluorescent pigments can be used as selection marker for TNFα:eGFP which 
is not activated in intact zebrafish. (b) Representative maximum projections 
show the different morphology and activation of TNFα::eGFP  at 1dpi YS of 
zebrafish with different treatment: injected with Apo-EVs, non-Apo-EVs and 
media underwent the same treatment.  Green arrows show TNFα+ cells that 
are not macrophage, yellow arrows show macrophages that express TNFα. 
(c) Quantification of the numbers of macrophages, TNFα+ cells and TNFα+ 
macrophages in the YS of zebrafish injected with Apo-EVs, non-Apo-EVs, 
media underwent treatment (Control group) and HBSS as well as intact 
zebrafish. Dev (Developmental) control represents intact zebrafish. (d) The 
percentage of TNFα activated macrophage in non-Apo-EVs injected 
xenografts is significantly higher than TNFα activated macrophages in Apo-
EVs injected zebrafish. (e) 48.3% of macrophages in the injection site of non-
Apo-EVs injected group were expressing TNFα while 3.8% of macrophages 
in the injection site of Apo-EVs injected group were expressing TNFα. 
Control group has 6% TNFα expressing macrophages of total macrophages 
in the YS. (Mean ± SEM, Mann Whitney test, **p<0.01, ***p<0.001. Scale bar 
= 20 µm).	
	
EVs especially Apo-EVs induced macrophages to display amoeboid 
phenotype as shown in figure 5.7. This change in morphology causes a 
change in the ratio of the macrophage cell surface to cell volume, which can 
be used as a read out for their activation. Therefore, the morphology of 
macrophages was further analysed.  Based on the morphological criteria, 
macrophages in YS in Apo-EVs injected zebrafish were analysed and 
compared to non-Apo-EVs injected xenografts and control group (figure 5.8). 
This analysis showed a significantly higher percentage of amoeboid 
(activated) macrophages in the YS of Apo-EVs injected zebrafish compared 
to non-Apo-EVs injected xenografts and control xenografts.	
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Figure 5.8 Apo-EVs activate macrophages	
(a) Representative images showing morphological details of macrophages 
using the surface tool in Imaris. (b) Photo shows segmented images using 
the surface tool in Imaris. i shows a fully activated (amoeboid) cell 
(surface/volume ratio < 0.6),  ii represents an activated cell (surface/volume 
ratio 0.6~0.8), iii shows a ramified cellac (surface/volume ratio 0.8~1). (c) 
Quantification of the percentage activation within macrophage population 
within YS in Apo-EVs injected zebrafish (n=8), non-Apo-EVs injected 
zebrafish (n=6) and control zebrafish (n=9). (Mean ± SEM, Mann Whitney 




This chapter has focused on establishing possible mechanisms underlying 
apoptosis promotion of BL growth.  I established a quick and reliable 
zebrafish model to investigate tumour-induced angiogenesis mediated by 
EVs from apoptotic BL cells. This provided the first in vivo evidence of the 
pro-angiogenic function of Apo-EVs and suggests a mechanism by which 
tumor apoptosis may promote tumor growth. Furthermore, the phenotypic 
observation of activated macrophages in the angiogenesis area, suggest that 
the pro-angiogenic action of EVs possibly may be due to 1) direct interaction 
with endothelial cells 2) modulation of macrophage behaviour.  
 
EVs contain various cargoes, such as DNA, mRNA, microRNA, growth 
factors, adhesion proteins, lipids, tissue factors and protease inhibitors, 
based upon their cellular origin and biogenesis pathway (Inal et al., 2012, 
Rak, 2013, Vader et al., 2014). In tumours, EVs have been implicated in the 
extracellular matrix remodelling, fibroblasts function modification, 
angiogenesis, tolerogenic immune response, drug resistance and modulation 
of the metastatic niche (Minciacchi et al., 2015, Taylor and Gercel-Taylor, 
2011, Muralidharan-Chari et al., 2009, Castellana et al., 2009, Zhuang et al., 
2012, Peinado et al., 2012, Lesnik et al., 2016). One obstacle to study EVs 
has been the technical challenges of isolating EVs due to their small size and 
sensitivity to stressful handling. Currently there is still no consensus isolation 
procedure and also the lack of widely accepted specific markers to identify 
functionally distinct subpopulations of EVs, including apoptosis-induced EVs. 
 
The conventional 3-step differential centrifugation protocol was used widely 
in the literature and a method which involved centrifugation (details see 
chapter 2) was developed by a previous student in our group and used for 
some experiments (data for figure 5.4).  The fragility of apoptotic cells and 
their susceptibility to damage from harsh isolation methods make the 
preparation and characterisation of Apo-EVs difficult.  Furthermore, in the 
need to study its function, it is desirable to avoid introducing additional 
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molecules or beads during separation of EVs. An optimal “gentle” and ‘clean’ 
method to produce and isolate EVs from UV treated BL cells were developed 
in our group during this project (shown in chapter 2). This method minimises 
extraneous stress without introducing beads or molecules during the 
production of EVs used for all the studies in this chapter except figure 5.4. 
 
The Nanoparticle Tracking Analysis (NTA) has been established as a more 
accurate way to quantify EVs than flow cytometry and was employed in this 
project to calculate EVs. NTA also provided a size profile to ensure the 
consistency of EVs amongst different EVs isolates. NTA results showed a 
clear correlation between the proportion of apoptotic cells and the number of 
EVs produced, which indicated the EVs produced from BL2 cell after UV 
treatment were apoptosis associated.  
 
In BL, where apoptosis is constitutively prominent, EVs are enriched in 
certain molecules, lipids, RNAs and extra-chromosomal DNA implying their 
possible role in a BL microenvironment. Therefore, after choosing the most 
suitable and reliable methods to isolate and characterize the EVs, I 
established a zebrafish model for study EVs-induced angiogenesis based on 
my findings in the previous chapter. I assume that EVs are not as sensitive 
as viable cells to temperature and are biologically active at 28.5oC. EVs 
xenografts were kept at 28.5oC to optimise zebrafish development. 	
	
The established zebrafish models allowed a quick assay of the pro-
angiogenesis ability of EVs. EVs from UV treated BL2 cells whose production 
was apoptosis-dependent were considered as Apo-EVs in this project. EVs 
from bcl2 transfected BL2 cells underwent the same treatment and were 
used as controls for non-Apo-EVs in this project.  Results showed that Apo-
EVs have a significantly higher ability to induce angiogenesis in zebrafish 
than non-Aop-EVs. Studies in cancer derived EVs demonstrate that EVs can 
directly interact with endothelial cells to induce tumour angiogenesis.  EVs 
from cancer cells harbour interleukin-6 (IL-6) and VEGF, the neutral 
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sphingomyelinase 2, potent pro-angiogenic factors, as well as other 
molecules able to interact with endothelial cells leading to enhanced 
endothelial cell invasion (Skog et al., 2008, Thompson et al., 2013, Kosaka et 
al., 2013). 	
	
Secretome as another source from tumour cells often display altered profile 
of macromolecules compared to the normal tissue from which they are 
derived (Paltridge et al., 2013, Taylor and Gercel-Taylor, 2011). Studies 
show that the altered composition secreted from tumour cells contributes to 
the acquisition and maintenance of the recognised hallmarks of cancer and 
malignant disease progression (Paltridge et al., 2013, Neilsen et al., 2011). .  
It is possible that apoptotic tumour cells may secret soluble products to 
promote tumour growth.  Therefore, secretome from apoptotic cells and their 
EVs were collected and compared. Secretome from apoptotic BL cells and 
their EVs showed a higher ability at inducing angiogenesis than from UV 
treated BL2-bcl2 cells and their EVs. This result suggested that apoptosis 
regulated the composition of secreted factors to promote tumour 
angiogenesis.  Now, it is accepted that secretome are composed of proteins, 
lipids, micro-RNAs (miRNA) and messenger RNA (mRNA) (Agrawal et al., 
2010, Iorio and Croce, 2012, Makridakis and Vlahou, 2010). Inactivation of 
proteins in the secretome by standard heat treatment showed decreased 
ability of inducing angiogenesis indicating that proteins in the secretome 
were important players for angiogenesis. It is possible that apoptosis not only 
produces soluble proteins but also modulates the molecular expression of 
EVs to further enhance tumour angiogenesis. These data indicated that 
apoptotic tumour cells may release EVs and soluble factors to promote 
angiogenesis by direct interaction with endothelial cells and/or fibroblasts.  	
 
Increased local vasculature in tumours is closely associated with cancer 
progression towards malignancy and is critically influenced by the presence 
of macrophage and their phenotypic state (Gurevich et al., 2018, Lin et al., 
2006, Williams et al., 2016). Therefore, another obvious candidate 
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mechanism for apoptosis induced angiogenesis is modulation of macrophage 
phenotype. Macrophages are critical regulators in a tumour 
microenvironment and are closely associated with tumour angiogenesis 
(Nathan, 2008, Sica and Mantovani, 2012). Macrophages acquire different 
morphology, biochemistry, and functions based on environmental cues. 
Through their diversity, macrophages are regulated to meet different needs. 
For example, macrophages are polarised to an M1 phenotype and produce 
inflammatory cytokines by inflammatory stimuli from invading pathogens.  In 
contrast, macrophages are polarised toward an M2 phenotype in a wound 
healing environment to help tissue repair (McWhorter et al., 2013). M2 
phenotype in a wound healing environment to help tissue repair 27. Despite 
the well-acknowledged consensus that macrophages are highly plastic and 
comprised of distinct subpopulations, the mechanism regulating the 
polarisation of macrophages still remains poorly defined (McWhorter et al., 
2013). Most studies of macrophage population diversity are carried out in 
vitro, for example, using monocyte-derived macrophages treated with 
specific stimuli. Macrophage subtypes are still poorly characterized in live 
animals. 
	  
In a tumour environment, especially solid tumours with high rates of 
apoptosis, for example in BL, macrophages have been shown to accumulate 
in tumours and promote tumour growth (Ford et al., 2015). To establish 
whether macrophages are modulated by Apo-EVs to a pro-tumour growth 
phenotype, I used Tg(mpeg1::mCherry/tnfα::eGFP) to observe the 
polarisation of macrophages in vivo. Results showed that Apo-EVs impacted 
on the morphology of macrophages towards an amoeboid phenotype and 
most of the macrophages were not expressing TNFα. In contrast, non-Apo-
EVs stimulated most of the macrophages to express TNFα. TNFα is a 
secreted pro-inflammatory cytokine that signals several cellular processes, 
including apoptosis, cell survival, and proliferation (Tartaglia et al., 1993, 
Cheng et al., 1994, Chan and Lenardo, 2000, Gupta, 2001).  TNFα 
expressing macrophages are generally considered as M1 polarised in 
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mammals (Parameswaran and Patial, 2010).  In wound healing and bacterial 
infection models, zebrafish Tg (mpeg1::mCherry/tnfα::eGFP) show that 
unpolarised macrophages move to the sites of inflammation where they 
become polarised to M1 phenotype  initially and later change to M2-like 
phenotype (Nguyen-Chi et al., 2015). In this xenograft model, Apo-EVs leads 
to macrophage activation but not TNFα expression suggest that Apo-EVs 
induce a M2 phenotype. Combined with the finding that Apo-EVs enhanced 
tumour angiogenesis indicated TNFα+ macrophages were not involved in the 
induction of angiogenesis in this model. However, during wound induced 
angiogenesis TNFα- M2 macrophage is involved in vessel remodelling after 
the initial sprouting (Gurevich et al., 2018).  
 
The morphology of macrophages has been used to indicate their activation 
status. For example, in vitro maturation of macrophages by stimulation of 
bone marrow-derived macrophages (BMDMs) with cytokines to M1 or M2 
polarization exhibited different cell morphologies: M1 cells displayed a round, 
pancake-like shape while M2 cells displayed cellular elongation (McWhorter 
et al., 2013).  In zebrafish, an amoeboid morphology of macrophage 
stimulated by pathological insults in brain are considered to reflect their 
activation (Karperien et al., 2013, Chia et al., 2018). By analysing the 
morphology of macrophages in EVs xenograft models, Apo-EVs displayed 





Chapter 6 General discussion 
6.1 Thesis objectives and summary of findings  
In my thesis I aimed to reveal how apoptotic tumour cells manipulate the 
tumour microenvironment to promote cancer, focusing on the mechanisms 
underlying their pro-angiogenesis roles. B cell lymphoma, prototypically BL 
was used as the model due to the extensive apoptosis and high infiltration of 
macrophages.  
Zebrafish was chosen as a model due to the ease of gene manipulation and 
translucency during the larval stages offering the opportunity of direct live-
imaging (Zhao et al., 2015, Trede et al., 2004).  Efforts were made to 
generate transgenic B lymphoma models and xenograft models in zebrafish.  
Initially I tried to induce B cell lymphoma in zebrafish by over-expressing the 
cmyc oncogene under the control of a specific B cell promoter constitutively, 
Tg(IgM1::cmyc-eGFP) or in an inducible manner, 
Tg(IgM1::CreERT2/IgM::lox-H2BmCherry-lox-cmyc-eGFP). Unfortunately, no 
detectable tumours were developed in transgenic zebrafish. Flow cytometry 
analysis showed normal distribution of cell populations in zebrafish kidney 
which is considered as the site of B cell development in Tg(IgM1::lox-
H2BmCherry-lox-cmyc-eGFP) and mCherry labelled cells were found in the 
lymphocyte population. The percentages of different cell populations in 
kidney are consistent with the literature (Traver, 2004, Chi et al., 2018). 
Further analysis of zebrafish kidney showed that there was a loss of 
lymphocyte populations in Tg(IgM1::cmyc-eGFP) and no detectable eGFP 
positive B-cells. These data suggest that the cmyc over-expression in IgM+ B 
cells might lead to cell death in zebrafish. However, further analysis on 
isolated lymphocytes from Tg(IgM1::cmyc-eGFP) fish is required to confirm 
this possibility. However, this has not been pursued because of time 
constraints. 
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Xenograft models using zebrafish larvae were also generated to visualise the 
direct interactions of tumour cells and host cells within the tumour 
microenvironment. Consistent with previous observations in mice, the 
suppression of apoptosis by over-expression of bcl2 in BL2 cells decreased 
their viability in zebrafish larvae (Ford et al., 2015). The mouse models of BL 
indicate that TAMs are attracted by apoptotic BL cells and accumulate within 
the BL microenvironment (Ford et al., 2015). To evaluate whether 
macrophage functions are modulated by apoptotic cells and might regulate 
BL cell survival in the zebrafish model, human monocyte derived 
macrophages that had been differentially polarized were co-transplanted with 
BL cells. Three treatment groups that potentially represented different 
phenotypes were compared: 1) ‘M0’ macrophages matured from monocytes 
without additional activation, 2) ‘M1’ macrophages matured from monocytes 
and activated by IFN-γ / lipopolysaccharide (LPS) and 3) M2-like 
macrophages matured from monocytes and activated by co-culture with 
apoptotic BL2 cells. Unexpectedly, the co-injection of BL2 and M2 
macrophages lead to mortality of the host, although M0 macrophage facilitate 
the survival of BL2 cells in zebrafish. These data suggest that apoptotic BL2 
cells can polarize host macrophages to a tumour promoting phenotype. M1 
macrophages on the other hand decreased the viability of BL2 cells which is 
consistent with previous studies that inflammatory macrophages constrain 
tumour growth (Sica and Mantovani, 2012, Shi and Shiao, 2018, Ostuni et 
al., 2015). 
 
EVs produced by apoptotic tumour cells were further investigated as the 
candidate mechanism for apoptotic BL2 cells modulating macrophage 
phenotype and the tumour microenvironment. An optimised gentle method 
developed by Dr Maggie Paterson in our group was used to generate intact 
EVs since their functional integrity was imperative. Apoptotic BL2 cells 
produce more EVs with different size distribution compared with BL2-bcl2 
cells. This suggests that altered EVs were produced by apoptotic BL2 cells 
compared with non-apoptotic cells. Using a zebrafish larval yolk sack 
 122 
angiogenesis assay, I provide the first in vivo evidence that Apo-EVs are pro-
angiogenic. Further analysis of the secretome from apoptotic BL2 cells as 
well as their Apo-EVs indicates that soluble protein component(s) in both 
mediate the pro-angiogenic function. To see whether the Apo-EVs polarise 
macrophages, macrophage reporter fish Tg(mpeg1::mCherry) with TNFα 
reporter Tg(tnfα::eGFP) were employed. I show that Apo-EVs modulated 
macrophages differently compared with non-Apo-EVs. Specifically, Apo-EVs 
promote macrophage activation but not TNFα expression in vivo.  
6.2 Zebrafish as a model to study cancer of immune cell 
origin 
The discussion here will focus on haemopoietic malignancies which are 
established by either transgenic technology or transplantation.  
 
Many transgenic tumour models in zebrafish induce tumours in liver, skin or 
the nervous system (Zhao et al., 2015, Mirbahai et al., 2011, Mizgirev and 
Revskoy, 2010, Shepard et al., 2005, Storer and Zon, 2010, Phelps et al., 
2009, Shin et al., 2012, Neumann et al., 2009, Santhakumar et al., 2012).  
The most well studied transgenic zebrafish model for malignancy in immune 
system is T-cell leukaemia which is also the first cancer model induced by 
transgenic technology in zebrafish. It was generated by overexpression of 
myc under the control of zebrafish rag2 promoter (Langenau et al., 2003, 
Langenau et al., 2005). 
 
T cell development starts relatively early in zebrafish with the general T cell 
marker lck starting to be expressed from around 4 dpf (Langenau et al., 
2004). The superficial bilateral location of the thymus also makes direct 
observation of T cell ontogeny and pathogenesis relatively easy (Langenau 
et al., 2004). However, the study of B cells is more problematic, as B cells 
are produced and mature in head kidney and firstly observed in 
Tg(IgM1::eGFP) at about 20 days post fertilization when the fish body is no 
longer transparent, making it difficult to access via conventional microscopy 
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techniques (Page et al., 2013). A recent study has shown that the previously 
widely recognised T cell leukaemia model, Tg(rag2::hmyc) is in fact a 
combination of B and T cell acute lymphoblastic leukaemias (Borga et al., 
2018).  The existence of pre-B cell malignancy in this model was for a long 
time ignored partially because the kidney of zebrafish lies deeply in the fish 
body.  These factors contributed to the failure of generating a transgenic B 
cell lymphoma model in zebrafish during the current project (discussed 
further below). 
 
6.2.1 B cell malignancy driven by myc in zebrafish 
Initially the study of cmyc focused on its roles in favouring malignancy 
including promoting cell-cycle progression and in blocking terminal 
differentiation (Nesbit et al., 1999, Vita and Henriksson, 2006).  More 
recently, the dual role of cmyc on both cell-cycle progression and apoptosis 
has been well established (Uribesalgo et al., 2012, Vita and Henriksson, 
2006). Askew, Cleveland, and colleagues used an IL-3-dependent myeloid 
cell line and showed that the constitutive expression of myc can cause 
apoptosis (Askew et al., 1991). This study also indicated that the absolute 
levels or perhaps kinetic pattern of myc expression appear to be decisive in 
determining the cellular response to myc (Askew et al., 1991).  Furthermore, 
cells at adequate concentrations of growth factors respond to heightened 
myc by increased proliferation whereas when these growth factors are 
limiting cells seem to respond to myc with enhanced apoptosis (Askew et al., 
1991).   Myc is seen to increase the sensitivity to apoptosis in premalignant 
cells, but not after malignant transformation (McMahon, 2014).  A number of 
studies have been concerned with understanding of how a cell reacts to myc 
activation and most of the mechanisms defined so far have involved the pro-
apoptotic p53 pathway, the pro-survival bcl2 pathway, or both (Knezevich et 
al., 2005, Ozdek et al., 2004).  In addition to the environmental modulation of 
cmyc function, cmyc activation levels is another determinant of cmyc function 
(Murphy et al., 2008).  Specifically, using genetic platforms to tightly control 
cmyc levels in a rheostat-like manner, Murphy et al. showed that modest 
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elevation of myc led to enhanced transformation while robust overexpression 
of myc caused a dramatic increase in apoptosis (Murphy et al., 2008). The 
specific reasons why the cmyc-expressing cells died in the Tg(IgM1::cmyc-
eGFP) were not investigated in this project. However, the expression levels 
of cmyc in B cells may be one of the explanations that Tg(IgM1::cmyc-eGFP) 
did not develop cancers. Another possibility is that, as many studies suggest, 
the myc driven cell death is a default function rather than cell-cycle 
progression and it is only by co-operating with changes in the apoptotic 
machinery that myc is able to transform cells. In the classical Eµ-myc 
transgenic mouse model, the 6 month latency period for tumours suggests 
that additional genetic changes must occur subsequent to myc 
overexpression (Jacobsen et al., 1994).  A later study strongly suggests that 
the secondary genetic change is inactivation of the p53 pathway (Eischen et 
al., 1999).  The loss of p53 function may allow the cells to tolerate elevated 
myc without undergoing apoptosis.  
Zebrafish so far is known to have three immunoglobulin heavy-chain classes, 
IgM, IgD and IgZ.  As the name of Tg(IgM1::cmyc-eGFP )  implied, this 
model only expressed cmyc in the major IgM-expressing B cell subset. A 
very recent paper published during the writing of this discussion carefully 
studied pre-B and pre-T cell acute lymphoblastic leukemias in zebrafish 
Tg(rag2::hmyc/lck:eGFP), where  a rag2 promoter drives human myc and a 
zebrafish lck promoter controls GFP expression. This study shows that myc 
may be oncogenic in only the IgZ-lineage (functionally analogous to 
mammalian IgA) in Tg(rag2::hmyc/lck::eGFP) (Borga et al., 2018). This is 
supported by another study that shows that the B cell development in 
zebrafish does not go through a Raghi CD79+IgH-µ+ pre–B cell stage (Liu et 
al., 2017). The differences lie in the development of B cells, especially the 
IgM-lineage whose development does not have a Pre–B cell stage in 
zebrafish indicating that IgM1 is not the best candidate promoter to drive the 
oncogene for mimicking human cancers. 
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6.2.2 Xenograft models in zebrafish for cancer research 
Zebrafish especially the embryo which has not developed a functional 
adaptive immune system have been widely employed as a tumour xenograft 
host to study angiogenesis and metastasis (Kirchberger et al., 2017).   
 
From a review of the literature, many tumour cell types including in vitro 
established cell lines and primary tumour derived cells can be engrafted to 
zebrafish (Kirchberger et al., 2017, Veinotte et al., 2014). Surprisingly, the 
BL2 cells I used in this study did not engraft successfully  and all  injected 
cells died within 4dpi. A possible explanation for this could be lack of key B 
cell survival factors in the zebrafish larvae, as normally mature B cells do not 
develop until two weeks post fertilization.  This hypothesis is supported by 
the observation that cells survive worse when fewer BL2 cells were 
transplanted which rules out nutrient deprivation mediated cell death, and it is 
known that BL2 cells produce autocrine factors that help their own growth in 
vitro (Beatty et al., 1997, Vockerodt et al., 2001). Therefore, The models 
established during this project can be used to identify factors that are key to 
the survival and growth of B lymphoma.  I showed in this model that 
macrophages modulated by apoptotic cells can in turn facilitate BL2 cells 
survival, although more work needs to be done to identify identify the 
macrophage-mediated molecular mechanisms that support BL2 cell growth.  
Published data show engraftment efficiency in zebrafish embryo varies with 
the type of transplanted cells, and this applies not only for tumour cells, but 
also for normal healthy cells, further indicating the importance of essential 
lineage specific microenvironmental cues for cell survival in zebrafish larval 
xenograft models. For example, healthy human CD34+ hematopoietic stem 
and progenitor cells from cord blood rapidly disappear after injection into 
zebrafish embryos while human melanocytes survive and become distributed 
into their normal microenvironment in the skin (Pruvot et al., 2011, Lee et al., 
2005). Therefore, zebrafish embryo is an amenable host to study tumour cell 
host interactions, but there are many factors that need to be taken into 
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account when interpreting the phenotype of certain type of tumour in this 
model.   
 
For human tumours, angiogenesis occurs when tumour cells grow to a 
certain size and require new blood vessels to bring in more nutrients and 
oxygen. In zebrafish xenograft models, induction of angiogenesis is often due 
to the release of pro-angiogenesis factors by tumour cell lines (Nicoli et al., 
2007, Zhao et al., 2016). In addition to tumour cell derived signal, the 
microenvironment is also important for induction of angiogenesis. In a 
zebrafish xenograft model exposing larvae carrying tumour cells to a hypoxic 
environment, enhances angiogenesis while the tumour cell size remains 
constant (Lee et al., 2009). The failure of BL2 cells to induce angiogenesis is 
probably due to their limited viability in zebrafish larvae and to not producing 
sufficient pro-angiogenic factors. Recent studies suggest that interactions 
between tumour cells and endothelial cells at early stages even without blood 
flow are crucial for tumour growth, thereby indicating that endothelial cells 
can support tumour cells in a paracrine manner (Zhao et al., 2016).  
Provision of a potential perivascular niche may provide a solution to aid BL2 
cell survival in zebrafish. 
 
Although the interpretation and quantification of metastasis and growth of 
tumours in zebrafish larvae differ in various published reports, studies with 
melanoma cells stand out as being the most robust in terms of tumour growth 
and ability to metastasise as xenografts.  Successful metastasis of tumour 
cells in zebrafish, (metastasis here refers to cells that are injected into 
peripheral tissue, and by their subsequent intravasation to lymph or blood 
vessels followed by extravasation from the circulation to seed at a distal site) 
seems to imply that the tumour is able to survive and proliferate as a single 
cell, and not to require a critical mass to do so (Lee et al., 2005, Teng et al., 
2013, Marques et al., 2009). This is consistent with the behaviour of the 
melanoma cells (A375) used in this project as a technical control, which 
demonstrated that single cell derived colonies survived and proliferated at 
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the CHT site.  In contrast, BL2 cells did not show such single cell 
autonomous behaviour and remained at the injection site. 
 
6.3 Apoptosis driven pro-tumour mechanisms 
Apoptotic tumour cells have been shown to promote angiogenesis, and 
accumulation of TAMs in aggressive B cell lymphomas.  However, how 
apoptotic tumour cells execute these functions is still unclear.   
 
EVs release by apoptotic cells is well documented and have been shown to 
play an important role in processes including immune suppression, antitumor 
immunity, and autoimmunity (Caruso and Poon, 2018). Apparently, the cell 
origin and ‘package’ mechanisms of EVs are closely associated with the 
contents and functions of EVs.  EVs released by tumour cells during 
apoptosis can serve as long range and long lasting signal carriers mediating 
the modulating function of apoptotic cells in a tumour microenvironment. 
Enhanced angiogenesis was also found when Apo-EVs were co-cultured 
with HUVECs indicating the direct interaction between Apo-EVs and 
endothelial cells can induce angiogenesis (unpublished work in our group). 
Furthermore, I also show that Apo-EVs driven angiogenesis is susceptible to 
standard heat treatment implying that a thermo-sensitive protein(s) from Apo-
EVs are required to mediate their interaction with endothelial cells. The cell-
cell interactions between tumour cells and endothelial cells have been shown 
to stimulate angiogenesis through the VEGFs family proteins and their 
associated receptors (De Palma et al., 2017).  It would be interesting to test if 
Apo-EVs are enriched with VEGF proteins. Another possible mechanism for 
Apo-EVs in modulating endothelial cells is via intercellular transfer of proteins 
or RNAs leading to the altered recipient cells.  This type of modulation 
mechanism for Apo-EVs was seen in an aggressive glioblastoma model 
where Apo-EVs affected mRNA splicing in recipient tumour cells (Pavlyukov 
et al., 2018).  
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Apoptotic tumour cells have been shown to activate macrophages to a pro-
angiogenic phenotype in aggressive B cell lymphoma (Ford et al., 2015). 
Apo-EVs modulated macrophages to an ameboid shape, which is generally 
considered as an activation state (Chia et al., 2018, Nguyen-Chi et al., 2017) 
and most activated macrophages were did not express TNFα. Previous 
studies in zebrafish showed that TNFα+ macrophages express high levels of 
the pro-inflammatory cytokines TNFβ, IL1β and IL6 while TNFα- 
macrophages express high levels of TGFβ, CCR2 and CXCR4β that are 
considered to be a specific phenotype of the M2 subtype (Nguyen-Chi et al., 
2017). Therefore the activated TNFα- macrophages induced by Apo-EVs are 
M2-like macrophages and this is in line with that the pro-tumour growth TAM 
that are generally considered to have a M2-like phenotype (Nathan, 2008, Li 
et al., 2018). A recent zebrafish wound angiogenesis study showed that pro-
inflammatory TNFα+ macrophages are necessary for early vessel sprouting 
through VEGFa expression and appears to downregulate TNFα during the 
anastomosis and vessel maturation process (Gurevich et al., 2018).  
Interestingly, Apo-EVs directly act on endothelial cells potentially through 
providing VEGFs (discussed previously) and simutaneously Apo-EVs induce 
a TNFα- phenotype in recruited macrophages that could contribute to the 
vessel remodeling during angiogenesis. 
 
6.4 Future work 
I have shown here that Apo-EVs play significant roles in inducing 
angiogenesis and to modulate macrophage function. I hypothesize that Apo-
EVs fulfil the angiogenesis process in a well-designed manner: the direct 
interaction with endothelial cells to start the angiogenesis process and the 
polarisation of macrophages for vessel maturation.  The next step forward is 
to reveal how Apo-EVs interact with endothelial cells and the roles of 
polarised macrophages polarised by Apo-EVs. 
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In order to identify pathways/factors that mediate Apo-EVs function, we are 
performing proteomics and RNA-seq analysis of Apo-EVs. Zebrafish 
xenograft models established here will be used to assess the functional 
contribution of candidate pathways. 
 
Apart from receptor signalling between Apo-EV and endothelial cells, another 
mechanism whereby Apo-EVs promote angiogenesis is by intercellular 
transfer. By fluorescent labelling of Apo-EVs and live imaging using my 
established zebrafish yolk sac angiogenesis models, it will be possible to 
reveal the internalisation process in real time. Single-cell RNA sequencing of 
the recipient endothelial cells would provide the means to a further 
understanding the pro-angiogenic mechanisms underlying Apo-EVs action. 
 
The data for Apo-EVs modulation of macrophage phenotype is of interest 
and promising. Further studies will focus on the phenotypes and functions of 
activated macrophage with or without TNFα expression.  
 
The Apo-EVs used in my study are derived from BL2 cells, it will be 
interesting to test whether Apo-EVs derived from other tumour cell lines or 
normal cells have similar function, which will shed light on how might 
apoptotic cell modulate its environment in general.  
 
There are multiple factors contributing to the failure to establish a zebrafish B 
cell lymphoma model using IgM1 driven cmyc expression as discussed 
previously. We are testing whether incorporating Tg(IgM1::cmyc-eGFP) into 
a p53-/- background might lead to B cell malignancy. IgM1 promoter might 
not be ideal for driving oncogene expression in immature B cells as a 
different developmental trajectory of B cell lineage exists in zebrafish. 
Therefore I would propose to test the CD79 promoter, which is newly 
characterised in zebrafish as a robust B cell specific promoter (Liu et al., 
2017). A mutant human cmyc derived from a human patient could also be 
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tested in combination with CD79 promoter to assess its tumourigenesis 
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